WO2022138718A1 - イムノグロブリン結合ポリペプチド - Google Patents
イムノグロブリン結合ポリペプチド Download PDFInfo
- Publication number
- WO2022138718A1 WO2022138718A1 PCT/JP2021/047570 JP2021047570W WO2022138718A1 WO 2022138718 A1 WO2022138718 A1 WO 2022138718A1 JP 2021047570 W JP2021047570 W JP 2021047570W WO 2022138718 A1 WO2022138718 A1 WO 2022138718A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- acid sequence
- immunoglobulin
- polypeptide
- seq
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 189
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 181
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 180
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 146
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 146
- 230000027455 binding Effects 0.000 title claims abstract description 137
- 150000001413 amino acids Chemical group 0.000 claims abstract description 83
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 77
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 55
- 239000003513 alkali Substances 0.000 claims abstract description 44
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 40
- 238000010828 elution Methods 0.000 claims abstract description 39
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 26
- 230000002378 acidificating effect Effects 0.000 claims abstract description 26
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 26
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 23
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims abstract description 18
- 239000012634 fragment Substances 0.000 claims abstract description 11
- 235000001014 amino acid Nutrition 0.000 claims description 117
- 229940024606 amino acid Drugs 0.000 claims description 81
- 235000004279 alanine Nutrition 0.000 claims description 69
- 235000014304 histidine Nutrition 0.000 claims description 68
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 63
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 51
- 239000004474 valine Chemical group 0.000 claims description 50
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 49
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 41
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 32
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 31
- 235000013922 glutamic acid Nutrition 0.000 claims description 30
- 239000004220 glutamic acid Substances 0.000 claims description 30
- 238000012986 modification Methods 0.000 claims description 29
- 230000004048 modification Effects 0.000 claims description 29
- 238000004519 manufacturing process Methods 0.000 claims description 28
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 25
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 22
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 21
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 17
- 239000013598 vector Substances 0.000 claims description 17
- 125000001931 aliphatic group Chemical group 0.000 claims description 16
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 13
- 229960000310 isoleucine Drugs 0.000 claims description 12
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 12
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 12
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 230000001131 transforming effect Effects 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 33
- 102000004169 proteins and genes Human genes 0.000 abstract description 28
- 125000003275 alpha amino acid group Chemical group 0.000 description 256
- 235000018977 lysine Nutrition 0.000 description 88
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 85
- 239000004472 Lysine Substances 0.000 description 84
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 59
- 235000004554 glutamine Nutrition 0.000 description 54
- 235000014393 valine Nutrition 0.000 description 48
- 238000006467 substitution reaction Methods 0.000 description 45
- 239000000499 gel Substances 0.000 description 39
- 108020004414 DNA Proteins 0.000 description 38
- 239000004475 Arginine Substances 0.000 description 36
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 36
- 241000588724 Escherichia coli Species 0.000 description 33
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 30
- 239000013613 expression plasmid Substances 0.000 description 30
- 230000000694 effects Effects 0.000 description 28
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 25
- 238000005259 measurement Methods 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 25
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 25
- 238000012360 testing method Methods 0.000 description 22
- 238000005406 washing Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 18
- 102220477127 C-X-C chemokine receptor type 4_N11A_mutation Human genes 0.000 description 16
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 14
- 229960002898 threonine Drugs 0.000 description 14
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 13
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 13
- 239000004473 Threonine Substances 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 229960005261 aspartic acid Drugs 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 12
- 229930027917 kanamycin Natural products 0.000 description 11
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 11
- 229960000318 kanamycin Drugs 0.000 description 11
- 229930182823 kanamycin A Natural products 0.000 description 11
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 229960001230 asparagine Drugs 0.000 description 10
- 235000009582 asparagine Nutrition 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 239000008363 phosphate buffer Substances 0.000 description 10
- 235000003704 aspartic acid Nutrition 0.000 description 9
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000011543 agarose gel Substances 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 150000007523 nucleic acids Chemical group 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 6
- 239000012670 alkaline solution Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 6
- 229940072221 immunoglobulins Drugs 0.000 description 6
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 5
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 150000001450 anions Chemical class 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 239000007979 citrate buffer Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000011218 seed culture Methods 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000012064 sodium phosphate buffer Substances 0.000 description 5
- 239000007160 ty medium Substances 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 150000002669 lysines Chemical class 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102220125026 rs886043836 Human genes 0.000 description 4
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Chemical group OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- 229960001269 glycine hydrochloride Drugs 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 102200066678 rs1554618767 Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241000589158 Agrobacterium Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- -1 IgM Proteins 0.000 description 1
- 238000012218 Kunkel's method Methods 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 102100035971 Molybdopterin molybdenumtransferase Human genes 0.000 description 1
- 101710119577 Molybdopterin molybdenumtransferase Proteins 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241001522306 Serinus serinus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- MTHMVLLKCNMJQL-UHFFFAOYSA-N oxalonitrile hydrobromide Chemical compound Br.N#CC#N MTHMVLLKCNMJQL-UHFFFAOYSA-N 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 102220005450 rs33939620 Human genes 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
Definitions
- the present invention relates to a polypeptide that binds to a polypeptide containing immunoglobulin or its Fc region. More specifically, the present invention has a binding activity to an immunoglobulin or a polypeptide containing an Fc region thereof, is excellent in stability under alkaline conditions (alkali stability), and is an immunoglobulin or a once bound immunoglobulin or It relates to a polypeptide capable of efficiently eluting the fragment in a weakly acidic region. Further, the present invention relates to a method for producing the polypeptide, a immobilized product of the polypeptide, a method for separating an immunoglobulin or a fragment thereof using the polypeptide, and the like.
- immunoglobulins also called antibodies
- advances in gene recombination technology have established techniques for producing human antibodies and humanized antibodies, and immunoglobulins have come to be put into practical use as antibody drugs in the medical field such as rheumatism and cancer.
- Immunoglobulin is mainly produced by animal cell culture, and affinity chromatography using a ligand having an immunoglobulin binding ability is widely used for its purification.
- affinity chromatography used for purification of immunoglobulin polypeptides such as protein A, protein L, and protein G, or immunoglobulin binding domains thereof are used as ligands that specifically bind to immunoglobulin.
- Patent Document 1 may be provided with excellent immunoglobulin binding ability and alkali stability by substituting a specific amino acid in the C domain of protein A or a specific amino acid residue in the Z domain of protein A. Has been reported. Further, Patent Document 2 reports that alkali stability can be provided by substituting the asparagine residue of protein A with another amino acid.
- An object of the present invention is to modify the amino acid sequence of the immunoglobulin binding domain of protein A so that the immunoglobulin having excellent alkali stability and the polypeptide containing the Fc region thereof once bound can be eluted in a weakly acidic region. Is to provide the peptide.
- the present inventor replaced serine at position 41 with an amino acid having a hydrophobic side chain, tyrosine or histidine in each immunoglobulin binding domain of protein A. , It has a binding activity to a polypeptide containing an immunoglobulin or its Fc region, has excellent alkali stability, and is efficient for a polypeptide containing an immunoglobulin or its Fc region once bound under mildly acidic mild conditions. It has been found that a polypeptide that can be eluted in the above can be obtained.
- glutamine at the 9th position is replaced with an amino acid or histidine having a hydrophobic aliphatic side chain, or glutamic acid at the 15th position is alanine or histidine and glutamic acid or alanine at the 24th position is glutamine. It has been found that by substituting with, the alkali stability and the elution property in the weakly acidic region can be further improved. The present invention has been completed by further studies based on such findings.
- Item 1 A polypeptide containing at least one immunoglobulin binding domain shown in any of the following (A) to (C).
- A) In the amino acid sequence shown in any of SEQ ID NOs: 1 to 15, an immunoglobulin binding domain containing an amino acid sequence in which a modification satisfying the following conditions (i) to (iv) is introduced: (i) Serine at position 41 is replaced with an amino acid, tyrosine, or histidine having a hydrophobic side chain. (ii) Glutamine at position 9 is substituted with an amino acid or histidine that is not substituted or has a hydrophobic aliphatic side chain.
- Glutamic acid or glutamine at position 15 is substituted or substituted with alanine, histidine, tyrosine or leucine.
- Glutamic acid or alanine at position 24 is unsubstituted, replaced with glutamine, histidine or alanine in the case of SEQ ID NOs: 1 to 12, or replaced with glutamine or histidine in the case of SEQ ID NOs: 13 to 15.
- B In the amino acid sequence shown in any of SEQ ID NOs: 1 to 15, a modification satisfying the above conditions (i) to (iv) has been introduced, and one or the number of amino acids at the site where the modification has not been made.
- Highly immunoglobulin binding domain. (C) In the amino acid sequence shown in any of SEQ ID NOs: 1 to 15, the modification satisfying the conditions (i) to (iv) is introduced, and the modification is made to the corresponding unmodified amino acid sequence. Immunoglobulin binding with 80% or more sequence identity at the absence site, equivalent or better alkali stability compared to a polypeptide consisting of the corresponding unmodified amino acid sequence, and higher IgG elution capacity in the weakly acidic region. domain.
- Item 2. The polypeptide according to Item 1, which is a monodomain-type peptide containing one immunoglobulin-binding domain selected from the immunoglobulin-binding domains shown in (A) to (C).
- Item 3. Item 2. The polypeptide according to Item 1, which is a multidomain type peptide in which two or more immunoglobulin binding domains selected from the immunoglobulin binding domains shown in (A) to (C) are linked.
- Item 4. Item 6. The polypeptide according to any one of Items 1 to 3, wherein in the amino acid sequence, glutamine at position 9 is replaced with an amino acid having a hydrophobic aliphatic side chain or histidine.
- glutamic acid or glutamine at position 15 is replaced with alanine or histidine
- glutamic acid at position 24 is glutamine in the case of SEQ ID NOs: 1 to 12, or alanine at position 24 in the case of SEQ ID NOs: 13 to 15.
- Item 6. The polypeptide according to any one of Items 1 to 4, which is substituted with glutamine.
- Item 6. The polypeptide according to any one of Items 1 to 5, wherein in the amino acid sequence, serine at position 41 is replaced with alanine, valine, leucine, phenylalanine, tyrosine, or histidine.
- Item 7. Item 6.
- Item 8. A DNA encoding the polypeptide according to any one of Items 1 to 7.
- Item 9. Item 8.
- Item 10. A transformant obtained by transforming a host with the recombinant vector according to Item 9.
- a carrier for immunoglobulin binding wherein the polypeptide according to any one of Items 1 to 7 is immobilized on an insoluble carrier.
- Item 13. Item 12. A method for separating an immunoglobulin or a fragment thereof, which separates a polypeptide containing an immunoglobulin or an Fc region thereof using the carrier for binding an immunoglobulin according to Item 12.
- Item 14. Item 13. An item 13 in which a polypeptide containing an immunoglobulin or an Fc region thereof is once bound to the carrier for binding an immunoglobulin, and then the polypeptide containing the immunoglobulin or an Fc region thereof is eluted under the conditions of pH 3 to 5. Separation method.
- the polypeptide of the present invention has an ability to bind to a polypeptide containing an immunoglobulin or its Fc region, and can maintain its ability to bind to a polypeptide containing an immunoglobulin or its Fc region even when exposed to alkaline conditions. Therefore, even if elution and washing with an alkaline solution are repeated, the decrease in the binding ability to the immunoglobulin or the polypeptide containing the Fc region thereof can be suppressed.
- the polypeptide of the present invention contains an immunoglobulin or its Fc region to be separated because the once bound immunoglobulin or a fragment thereof can be efficiently eluted under mild conditions of weak acidity (pH about 3 to 5). Degeneration of polypeptides can be suppressed.
- glycine G
- alanine A
- valine Val
- Leu L
- isoleucine I
- Phe phenylalanine
- Tyr tyrosine
- Trp Tryptophan
- Serin Serin
- Seronin Thr
- Cystein Cystein
- Met Methionin
- Met Methionin
- Glutamic acid Glu
- Aspartic acid Aspartic acid (Asn) is N
- glutamine Gln
- lysine Lys
- arginine Arg
- Histidine Histidine
- Pro proline
- expressions such as “Q9V” and “Q9V / S41V” are notations for amino acid substitutions.
- “Q9V” means that glutamine at the 9-position from the N-terminal side in a specific amino acid sequence is replaced with valine.
- “Q9V / S41V” means that glutamine at the 9th position from the N-terminal side in a specific amino acid sequence is replaced with valine, and serine at the 41st position from the N-terminal side is replaced with valine.
- amino acid having a hydrophobic side chain includes alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, and tryptophan.
- amino acid having a hydrophobic aliphatic side chain includes alanine, valine, leucine, isoleucine, and methionine.
- polypeptide of the present invention includes a polypeptide containing at least one immunoglobulin binding domain shown in (A) below.
- A In the amino acid sequence shown in any of SEQ ID NOs: 1 to 15, an immunoglobulin binding domain containing an amino acid sequence in which a modification satisfying the following conditions (i) to (iv) is introduced:
- Serine at position 41 is replaced with an amino acid having a hydrophobic side chain, tyrosine, or histidine.
- Glutamine at position 9 is substituted with an amino acid or histidine that is not substituted or has a hydrophobic aliphatic side chain.
- Glutamic acid or glutamine at position 15 is substituted or substituted with alanine, histidine, tyrosine or leucine.
- Glutamic acid or alanine at position 24 is unsubstituted, replaced with glutamine, histidine or alanine in the case of SEQ ID NOs: 1 to 12, or replaced with glutamine or histidine in the case of SEQ ID NOs: 13 to 15.
- Each amino acid sequence shown in SEQ ID NOs: 1 to 15 is the amino acid sequence of the wild-type immunoglobulin binding domain (A, B, C, D, E) of protein A derived from Staphylococcus aureus and its variants. Is.
- SEQ ID NO: 1 is a wild-type C domain
- SEQ ID NOs: 2 and 3 are variants of C domain
- SEQ ID NO: 4 is a wild-type A domain
- SEQ ID NOs: 5 and 6 are variants of A domain
- Is a wild type B domain SEQ ID NOs: 8 and 9 are variants of the B domain
- SEQ ID NO: 10 is a wild type D domain
- SEQ ID NOs: 11 and 12 are variants of the D domain
- SEQ ID NO: 13 is a wild type E domain
- SEQ ID NO: 14 and 15 are variants of the E domain.
- amino acid sequence shown in SEQ ID NO: 2 in the amino acid sequence of the wild type C domain (SEQ ID NO: 1), lysine at position 4 is replaced with alanine, lysine at position 7 is replaced with threonine, and lysine at position 35 is replaced with arginine. It is an amino acid sequence in which valine at position 40 is replaced with lysine, glutamic acid at position 43 is replaced with lysine, alanine at position 46 is replaced with lysine, and asparagic acid at position 53 is replaced with lysine.
- amino acid sequence shown in SEQ ID NO: 3 in the amino acid sequence of the wild type C domain (SEQ ID NO: 1), lysine at position 4 is replaced with alanine, lysine at position 7 is replaced with threonine, and lysine at position 35 is replaced with arginine.
- the amino acid sequence is such that the lysine at position 42 is replaced with alanine, the lysine at position 49 is replaced with arginine, the lysine at position 50 is replaced with arginine, and the lysine at position 58 is replaced with arginine.
- amino acid sequence shown in SEQ ID NO: 5 in the amino acid sequence of the wild type A domain (SEQ ID NO: 4), asparagine at position 4 is replaced with alanine, lysine at position 7 is replaced with threonine, and lysine at position 35 is replaced with arginine. It is an amino acid sequence in which glutamine at position 40 is replaced with lysine, alanine at position 43 is replaced with lysine, serine at position 46 is replaced with lysine, and glutamine at position 53 is replaced with lysine.
- sequences after the 40th position are lysine-rich due to the introduction of lysine at the 40th, 43rd, 46th, and 53rd positions, which facilitates immobilization on the carrier. ing.
- amino acid sequence shown in SEQ ID NO: 6 in the amino acid sequence of the wild type A domain (SEQ ID NO: 4), asparagine at position 4 is replaced with alanine, lysine at position 7 is replaced with threonine, and lysine at position 35 is replaced with arginine.
- amino acid sequence shown in SEQ ID NO: 8 in the amino acid sequence of the wild type B domain (SEQ ID NO: 7), lysine at position 4 is replaced with alanine, lysine at position 7 is replaced with threonine, and lysine at position 35 is replaced with arginine. It is an amino acid sequence in which glutamine at position 40 is replaced with lysine, asparagine at position 43 is replaced with lysine, alanine at position 46 is replaced with lysine, and asparagic acid at position 53 is replaced with lysine.
- amino acid sequence shown in SEQ ID NO: 9 in the amino acid sequence of the wild type B domain (SEQ ID NO: 7), lysine at position 4 is replaced with alanine, lysine at position 7 is replaced with threonine, and lysine at position 35 is replaced with arginine. It is an amino acid sequence in which the lysine at position 49 is replaced with arginine, the lysine at position 50 is replaced with arginine, and the lysine at position 58 is replaced with arginine.
- amino acid sequence shown in SEQ ID NO: 11 in the amino acid sequence of the wild type D domain (SEQ ID NO: 10), asparagine at position 4 is replaced with alanine, lysine at position 7 is replaced with threonine, and lysine at position 35 is replaced with arginine. It is an amino acid sequence in which glutamine at position 40 is replaced with lysine, alanine at position 43 is replaced with lysine, glycine at position 46 is replaced with lysine, and glutamine at position 53 is replaced with lysine.
- amino acid sequence shown in SEQ ID NO: 12 asparagine at position 4 is replaced with alanine, lysine at position 7 is replaced with threonine, and lysine at position 35 is replaced with arginine in the amino acid sequence of the wild type D domain (SEQ ID NO: 10). It is an amino acid sequence in which threonine at position 42 is replaced with alanine, lysine at position 49 is replaced with arginine, lysine at position 50 is replaced with arginine, and lysine at position 58 is replaced with arginine.
- glutamine at position 4 is replaced with alanine
- glutamine at position 7 is replaced with threonine
- lysine at position 35 is replaced with arginine in the amino acid sequence of the wild-type E domain (SEQ ID NO: 13).
- glutamine at position 40 is replaced with lysine
- aspartic acid at position 43 is replaced with lysine
- glycine at position 46 is replaced with lysine
- aspartic acid at position 53 is replaced with lysine.
- glutamine at position 4 is replaced with alanine
- glutamine at position 7 is replaced with threonine
- lysine at position 35 is replaced with arginine in the amino acid sequence of the wild-type E domain (SEQ ID NO: 13). It is an amino acid sequence in which glutamine at position 49 is replaced with arginine, lysine at position 50 is replaced with arginine, and lysine at position 58 is replaced with arginine.
- the immunoglobulin binding domain of protein A has three ⁇ -helices, a first ⁇ -helix, a second ⁇ -helix, and a third ⁇ -helix, from the N-terminal side.
- Serine at position 41 in each amino acid sequence shown in SEQ ID NOs: 1 to 15 is conserved in all immunoglobulin-binding domains (A to E), and is the third ⁇ -helix of the three ⁇ -helices of the immunoglobulin-binding domain. It exists in the helix, forms a connection with the second ⁇ -helix, and interacts with the first ⁇ -helix.
- this serine at position 41 By substituting this serine at position 41 with an amino acid having a hydrophobic side chain, tyrosine, or histidine, the hydrophobic interaction between amino acids in the immunoglobulin binding domain can be enhanced and the alkali stability can be improved. ..
- the 41-position serine is located behind the ⁇ -helix structure of the 9-position glutamine, the 10-position glutamine, and the 11-position asparagine that form the immunoglobulin binding site in the 1st ⁇ -helix, and the 41-position serine is used. Substitution with amino acids having hydrophobic side chains, tyrosine or histidine is thought to affect the IgG binding structure they form.
- amino acid in which serine at position 41 in each amino acid sequence shown in SEQ ID NOs: 1 to 15 is substituted may be substituted with an amino acid having a hydrophobic side chain, tyrosine, or histidine, preferably alanine, valine, and the like.
- amino acid having a hydrophobic side chain, tyrosine, or histidine preferably alanine, valine, and the like. Examples include leucine, phenylalanine, tyrosine, or histidine.
- Glutamine at position 9 in each amino acid sequence shown in SEQ ID NOs: 1 to 15 is one of the IgG binding sites and contributes to binding to IgG by forming a hydrogen bond with serine at position 254 of IgG.
- the glutamine at position 9 in each of the amino acid sequences shown in SEQ ID NOs: 1 to 15 may be unsubstituted or substituted with an amino acid having a hydrophobic aliphatic side chain or histidine.
- glutamine at position 9 in each amino acid sequence shown in SEQ ID NOs: 1 to 15 is replaced with an amino acid having a hydrophobic aliphatic side chain or histidine, the alkali stability is further improved and the weakly acidic region is used. Elution can be enhanced.
- each amino acid sequence shown in SEQ ID NOs: 1 to 15 the amino acids at positions 41 and 9 are spatially close to each other, so that each amino acid sequence shown in SEQ ID NOs: 1 to 15 is located.
- the amino acid having a hydrophobic aliphatic side chain or histidine at the 9th position in the above, the amino acid having a hydrophobic side chain, tyrosine, or histidine existing at the 41st position and the hydrophobic fat existing at the 9th position
- the binding activity in the weakly acidic region can be reduced by reducing the interconnection with IgG while further improving the alkali stability by interacting with an amino acid having a group side chain or histidine.
- amino acid in which the 9-position glutamine in each amino acid sequence shown in SEQ ID NOs: 1 to 15 is substituted examples include alanine, valine, leucine, isoleucine, or histidine, and more preferably alanine, valine, leucine, or histidine. Be done.
- Glutamic acid or glutamine at position 15 in each amino acid sequence shown in SEQ ID NOs: 1 to 15 may be unsubstituted and alanine.
- Histidine, tyrosine or leucine may be substituted.
- the glutamic acid at position 24 in each amino acid sequence shown in SEQ ID NOs: 1 to 12 may be unsubstituted or substituted with glutamine, histidine or alanine.
- the alanine at position 24 in each amino acid sequence shown in SEQ ID NOs: 13 to 15 may be unsubstituted or substituted with glutamine or histidine.
- immunoglobulin binding domain of (A) those having the amino acid sequences shown in the following (1) to (5) can be mentioned.
- (1) In each amino acid sequence shown in SEQ ID NOs: 1 to 15, an amino acid sequence in which the 9th, 15th and 24th positions are unsubstituted and the 41st position is substituted with valine, phenylalanine, tyrosine or histidine.
- positions 15 and 24 are unsubstituted, position 9 is substituted with leucine, and position 41 is valine, leucine, phenylalanine, alanine, tyrosine, or histidine. Amino acid sequence substituted with.
- positions 15 and 24 are unsubstituted, position 9 is replaced with alanine, and position 41 is replaced with phenylalanine, valine, tyrosine, or histidine.
- Amino acid sequence (6) In each amino acid sequence shown in SEQ ID NOs: 1 to 15, amino acids in which positions 15 and 24 are unsubstituted, position 9 is substituted with isoleucine, and serine at position 41 is substituted with valine or alanine. arrangement.
- a polypeptide containing at least one immunoglobulin binding domain corresponding to any one of the following (B) and (C) can be mentioned.
- the immunoglobulin-binding domains of (B) and (C) are variants of the immunoglobulin-binding domain of (A), and are at positions 9, 15, 24, and in the amino acid sequences shown in SEQ ID NOs: 1 to 15.
- the mode of amino acid substitution introduced at position 41, the preferred amino acid substitution site, and the like are the same as in the case of the immunoglobulin binding domain of (A) above.
- the "amino acid at the site where the modification has not been made” means that the amino acid sequences shown in SEQ ID NOs: 1 to 15 are modified by satisfying the conditions of (i) to (iv).
- the positions other than the 41st and 9th positions are not used.
- Amino acids correspond to "amino acids at the site where the modification has not been made".
- the 41st, 15th and 24th positions are substituted with amino acids, and the 9th position is not amino acid substituted, the 41st, 15th and 24th positions are substituted.
- Amino acids other than the position correspond to "amino acids at the site where the modification has not been made".
- the modification of the amino acid introduced in the immunoglobulin binding domain of (B) may include only one modification (eg, substitution) from substitutions, additions, insertions, and deletions. It may include more than a species of modification (eg, substitution and insertion).
- the number of amino acids to be modified may be one, a plurality or several, for example, 1 to 13, preferably 1 to 6, 1 to 5, 1 to 1. 4 pieces, 1 to 3 pieces, 1 or 2 pieces, or 1 piece may be mentioned.
- the "corresponding unmodified amino acid sequence” refers to the base amino acid sequence, for example, if it is a modification of the amino acid sequence shown in SEQ ID NO: 1. , Refers to the amino acid sequence shown in SEQ ID NO: 1.
- sequence identity of the unmodified site means an amino acid other than the amino acid substituted by the modification satisfying the conditions of (i) to (iv). Refers to the sequence identity calculated by comparing the amino acid sequences extracted from.
- amino acids other than the 41st position are used.
- sequence identity calculated by comparing the amino acid sequences (amino acid sequences excluding the 41st position) extracted from the above corresponds to "sequence identity of the site not modified". Further, for example, when the 41st and 9th positions are amino acid substituted and the 15th and 24th positions are not amino acid substituted by the modification satisfying the conditions (i) to (iv), the positions other than the 41st and 9th positions are not substituted.
- sequence identity calculated by comparing the amino acid sequences obtained by extracting the amino acids corresponds to "the sequence identity of the unmodified site". Further, for example, by modifying the conditions of (i) to (iv) above, the 41st, 15th and 24th positions are substituted with amino acids, and the 9th position is not amino acid substituted, the 41st, 15th and 24th positions are substituted.
- sequence identity calculated by comparing the amino acid sequences (amino acid sequences excluding the 41st, 15th, and 24th positions) extracted from amino acids other than the above corresponds to "sequence identity of the unmodified site". do.
- sequence identity means BLAST PACKAGE [sgi32 bit edition, Version 2.0.12; available from National Center for Biotechnology Information (NCB)).
- NCB National Center for Biotechnology Information
- the sequence identity may be 80% or more, preferably 85% or more, more preferably 90% or more, still more preferably 95% or more.
- the immunoglobulin binding domain of (B) and (C) at least the asparagine at the 3-position in each amino acid sequence shown in SEQ ID NOs: 1 to 12 is replaced with alanine, valine, or aspartic acid. Things can be mentioned. Further, as one embodiment of the immunoglobulin binding domain of (B) and (C), at least alanine at the 3-position in each amino acid sequence shown in SEQ ID NOs: 13 to 15 is replaced with valine or aspartic acid. Be done.
- At least alanine, glutamine, asparagine, or lysine at the 4-position in each amino acid sequence shown in SEQ ID NOs: 1 to 15 is valine, histidine, arginine. , Or those substituted with isoleucine.
- immunoglobulin binding domain of (B) and (C) at least asparagine at position 6 in each amino acid sequence shown in SEQ ID NOs: 1 to 12 is replaced with alanine, valine, glutamine, or aspartic acid. There is something that is. Further, as one embodiment of the immunoglobulin binding domain of (B) and (C), at least aspartic acid at position 6 in each amino acid sequence shown in SEQ ID NOs: 13 to 15 is replaced with alanine, glutamine, or valine. Can be mentioned.
- At least threonine or lysine at position 7 in each amino acid sequence shown in SEQ ID NOs: 1 to 12, 14 and 15 is glutamic acid, histidine, arginine, and the like. Alternatively, those substituted with valine can be mentioned. Further, as one embodiment of the immunoglobulin binding domain of (B) and (C), at least glutamic acid at position 7 in the amino acid sequence shown in SEQ ID NO: 13 is replaced with histidine, arginine, or valine. ..
- At least asparagine or serine at position 11 in each amino acid sequence shown in SEQ ID NOs: 1 to 15 is alanine, valine, histidine, glutamine, or arginine. The one replaced with is mentioned.
- the amino acid sequences shown in SEQ ID NOs: 1 to 15 are modified to satisfy the conditions of (i) to (iv). In addition, at least those having the following amino acid substitutions can be mentioned.
- the 11th position is replaced with alanine, glutamine, histidine or arginine.
- the 7-position is replaced with glutamic acid (in the case of SEQ ID NO: 13, the 7-position is not substituted).
- the 4-position is replaced with isoleucine, the 7-position is replaced with arginine or glutamic acid in the case of SEQ ID NOs: 1 to 12, 14 and 15, or the 7-position is substituted or replaced with arginine in the case of SEQ ID NO: 13. 11th place is replaced with alanine.
- the 4-position is replaced with isoleucine or valine, and in the case of SEQ ID NOs: 1 to 12, 14 and 15, the 7-position is replaced with glutamic acid (in the case of SEQ ID NO: 13, the 7-position is not substituted).
- 3-position is replaced with aspartic acid, 6-position is replaced with asparagic acid in the case of SEQ ID NOs: 1 to 12, 6-position is not substituted in the case of SEQ ID NOs: 13 to 15, SEQ ID NOs: 1-12, 14 and In the case of 15, the 7-position is replaced with valine or glutamic acid, or in the case of SEQ ID NO: 13, the 7-position is unsubstituted or replaced with valine, and the 11-position is replaced with alanine.
- the lysine substituted at the 40th, 43rd, 46th, 49th, 50th, 53rd, and 58th positions plays a role of facilitating immobilization on the carrier (B).
- C as a preferred embodiment of the immunoglobulin binding domain, 4 or more lysines, preferably 6 of the 40, 43, 46, 49, 50, 53, and 58 positions. More than one lysine, more preferably all lysines, may not be mutated (substituted and / or deleted).
- the alkali stability is equal to or higher than that of the polypeptide, and the IgG elution ability is high in the weakly acidic region.
- Means that there is a binding activity to IgG, and the residual activity after alkali treatment measured under the following measurement condition 1 is the corresponding unmodified amino acid sequence measured under the same conditions (base SEQ ID NOs: 1 to 15).
- the elution rate in weak acidity measured under the following measurement condition 2 is equal to or higher than the residual activity of the polypeptide consisting of any of the amino acid sequences) after alkali treatment, and the corresponding unmodified unmodified one measured under the same conditions. It means that it is higher than the dissolution rate in weak acidity when a polypeptide consisting of an amino acid sequence is used.
- the residual activity after alkali treatment measured under the following measurement condition 1 is 1.1 compared to the residual activity after alkali treatment of the polypeptide consisting of the corresponding unmodified amino acid sequence measured under the same conditions.
- the elution rate in weak acidity which is more than doubled and is measured under the following measurement condition 2, is the elution rate in weak acidity when a polypeptide consisting of the corresponding unmodified amino acid sequence measured under the same conditions is used.
- the alkali stability is equal to or higher than that of the polypeptide consisting of the corresponding unmodified amino acid sequence, and the IgG elution ability is high in the weakly acidic region.
- I can say.
- the immunoglobulin binding domain of (B) and (C) the residual activity after alkali treatment measured under the following measurement condition 1 is after alkali treatment of the polypeptide consisting of the corresponding unmodified amino acid sequence measured under the same conditions.
- immunoglobulin binding domain of (B) and (C) a polypeptide consisting of the corresponding unmodified amino acid sequence whose elution rate in weak acidity measured under the following measurement condition 2 was measured under the same conditions was used. It is preferably 1.3 times or more, more preferably 1.3 to 1.52 times, and more preferably 1.4 to 1.55 times, as compared with the elution rate in weak acidity. More preferred.
- ⁇ Measurement condition 1 (measurement of residual activity after alkaline treatment)>
- the polypeptide immobilized on the agarose gel carrier is washed 3 times with a 0.1 M NaOH aqueous solution, replaced with the same alkaline solution, and then kept warm at 25 ° C. for 68 hours (alkaline treatment). Then, after washing with PBS, the amount of human IgG bound (mg / ml gel) is measured. Even when not treated with alkali, the amount of human IgG bound to the polypeptide immobilized on the agarose gel carrier (mg / ml gel) is measured.
- the ratio of the binding amount of human IgG of the polypeptide after the alkali treatment is calculated as "residual activity (%) after the alkali treatment", assuming that the binding amount of human IgG of the polypeptide without alkali treatment is 100%.
- ⁇ Measurement condition 2 (measurement of elution rate in weak acidity)> Human IgG is bound to the polypeptide immobilized on the agarose gel carrier. The immobilized polypeptide is then washed with PBS and then eluting human IgG bound to the immobilized polypeptide using 0.1 M citrate buffer (pH 4.0). Subsequently, 0.1 M glycine hydrochloride buffer (pH 2.8) is used to elute the remaining human IgG bound to the immobilized polypeptide. The amount of human IgG eluted at pH 4.0 and the amount of human IgG eluted at pH 2.8 are measured.
- the total amount of human IgG eluted at pH 4.0 and the amount of human IgG eluted at pH 2.8 is 100%, and the ratio of the amount of human IgG eluted at pH 4.0 is the elution rate (%) in weak acidity. calculate.
- the polypeptide of the present invention may be a single domain type polypeptide having one immunoglobulin-binding domain, or may be a multi-domain type polypeptide in which two or more immunoglobulin-binding domains are linked.
- the polypeptide of the present invention is a multi-domain type polypeptide, there is an advantage that the binding ability of the immunoglobulin or the Fc region-containing polypeptide thereof is increased.
- polypeptide of the present invention is a monodomain type polypeptide, it is sufficient that one of the immunoglobulin binding domains (A) to (C) is contained.
- the immunoglobulin binding domain containing the amino acid sequences shown in SEQ ID NOs: 2, 5, 8, 11 and 14 as a base (hereinafter referred to as "lysine rich domain"). Since there is also a carrier-binding property, when the immunoglobulin-binding domain is used as a monodomain-type polypeptide, it is not necessary to add an amino acid sequence having a carrier-binding property. In order to further improve the binding property to the carrier, an amino acid sequence having the binding property to the carrier may be added.
- the immunoglobulin binding domains of (A) to (C) the immunoglobulin binding containing the amino acid sequences shown in SEQ ID NOs: 1, 3, 4, 6, 7, 9, 10, 12, 13, and 15 as a base.
- a domain hereinafter, also referred to as "lysine non-rich domain”
- an amino acid sequence having binding property to the carrier is added in order to impart binding property to the carrier. It is preferable that it is.
- the polypeptide of the present invention is a multidomain type polypeptide, it suffices to contain at least one domain among the immunoglobulin binding domains of (A) to (C), and (A) to ((A) to ( It may consist of two or more domains within the immunoglobulin binding domain of C)), and one or more of the immunoglobulin binding domains of (A) to (C) and protein A. It may contain one or more of each immunoglobulin binding domain constituting the protein L and each immunoglobulin binding domain constituting the protein L.
- the polypeptide of the present invention is a multi-domain type polypeptide
- all of the constituent immunoglobulin-binding domains are (A) from the viewpoint of providing even better alkali stability and antibody elution characteristics in a weakly acidic region. )-(C), preferably composed of any of the immunoglobulin binding domains.
- the total number of linked immunoglobulin-binding domains may be 2 or more, preferably 2 to 10, and more preferably 2 to 6. Individuals can be mentioned.
- each of the constituent immunoglobulin-binding domains may have its C-terminal and N-terminal directly linked, and each immunoglobulin-binding domain has one interval. It may be linked via ⁇ 40, preferably 1-10 amino acid residues.
- polypeptide of the present invention is made into a multi-domain type polypeptide, a structure in which one or more lysine-free domains and one or more lysine-rich domains are linked; more preferably, lysine-non-rich.
- an amino acid sequence having the binding property to the carrier is added in order to impart the binding property to the carrier. Is preferable.
- amino acid sequence of the "amino acid sequence having binding property to the carrier” examples include an amino acid sequence in which 1 to 15, preferably 3 to 10, and more preferably 4 to 8 lysines are linked. This linkage sequence may contain amino acids other than lysine in addition to lysine.
- an amino acid sequence having a binding property to a carrier it may be added to either the N-terminal side or the C-terminal side, but it is preferably the C-terminal.
- a polypeptide having other functions, a peptide tag, etc. are added to the N-terminal side or the C-terminal side in order to improve the expression of the polypeptide, impart the ease of purification, and the like. You may.
- the number of amino acids added to the N-terminal side and / or the C-terminal side of the polypeptide of the present invention is not particularly limited, but is, for example, 1 to 400, preferably 1 to 100, and further. The number is preferably 1 to 30.
- DNA encoding the polypeptide of the present invention is, for example, DNA encoding protein A derived from Staphylococcus aureus. Can be obtained by obtaining a DNA encoding a target immunoglobulin binding domain by PCR or the like and introducing a mutation into the DNA so that a desired amino acid substitution or the like is introduced into the DNA. Further, the DNA of the present invention can also be artificially synthesized by a gene synthesis method.
- the DNA encoding the wild-type protein A derived from Staphylococcus aureus is known as, for example, the base sequence shown in SEQ ID NO: 16, and is obtained from Staphylococcus aureus by a conventional method using PCR. Can be isolated.
- the DNA encoding wild-type protein A can also be artificially synthesized by a gene synthesis method.
- a method for introducing a specific mutation into a specific site of a base sequence is known, and for example, a site-specific mutation introduction method for DNA can be used.
- a site-specific mutation introduction method for DNA can be used as a specific method for converting a base in DNA.
- a commercially available kit can be used as a specific method for converting a base in DNA.
- the base sequence of DNA in which a mutation has been introduced into the base sequence can be confirmed using a DNA sequencer. Once the base sequence is determined, the DNA encoding the polypeptide is obtained by chemical synthesis, PCR using a cloned probe as a template, or hybridization using a DNA fragment having the base sequence as a probe. be able to.
- a mutant type of DNA encoding the peptide having the same function as before the mutation by a site-specific mutagenesis method or the like.
- Introducing a mutation into the DNA encoding the peptide can be carried out by a known method such as the Kunkel method, the Gapped doublex method, or the megaprimer PCR method.
- the DNA of the present invention is preferably one in which the frequency of codon utilization is optimized for the host.
- DNA whose codon utilization frequency is optimized for Escherichia coli is suitable.
- Recombinant vector A recombinant vector containing DNA encoding the polypeptide of the present invention (hereinafter, also referred to as “recombinant vector of the present invention”) can be obtained by inserting the DNA of the present invention into an expression vector. be able to.
- the recombinant vector of the present invention contains a regulatory factor such as a promoter operably linked to the DNA of the present invention.
- a regulatory factor such as a promoter is typically mentioned, but if necessary, a transcription element such as an enhancer, a CCAAT box, a TATA box, or an SPI site may be included.
- operably linked means that the DNA of the present invention is linked to various regulatory factors such as promoters and enhancers that regulate the DNA of the present invention in a state in which they can act in the host cell.
- the expression vector a vector constructed from phages, plasmids, or viruses that can grow autonomously in the host for gene recombination is suitable.
- Such expression vectors are known, and for example, commercially available expression vectors include pQE-based vector (Qiagen Co., Ltd.), pDR540, pRIT2T (GE Healthcare Bioscience Co., Ltd.), and pET-based vector (Merck). Co., Ltd.) and the like.
- the expression vector may be used by selecting an appropriate combination with the host cell.
- Escherichia coli when Escherichia coli is used as the host cell, a combination of a pET system vector and a BL21 (DE3) Escherichia coli strain, or a pDR540 vector and JM109 Escherichia coli. A combination of strains and the like is preferable.
- Transformant of the present invention can be obtained by transforming a host with the recombinant vector of the present invention.
- the host used for producing the transformant is not particularly limited as long as the recombinant vector is stable, autonomously proliferative, and can express the trait of an exogenous gene, and is not particularly limited.
- Escherichia coli and the like Bacteria belonging to the genus Escherichia, the genus Bacillus such as Bacillus subtilis, the genus Pseudomonas putida, etc .; yeast and the like are preferable examples, but other animal cells, insect cells, etc. , Plants and the like. Of these, Escherichia coli is particularly preferable.
- the transformant of the present invention can be obtained by introducing the recombinant vector of the present invention into the host, and the conditions for introducing the recombinant vector into the host may be appropriately set according to the type of host and the like.
- the host is a bacterium, for example, a method using competent cells treated with calcium ions, an electroporation method, and the like can be mentioned.
- the host is yeast, for example, an electroporation method, a spheroplast method, a lithium acetate method and the like can be mentioned.
- the host is an animal cell, for example, an electroporation method, a calcium phosphate method, a lipofection method and the like can be mentioned.
- the host is an insect cell, for example, a calcium phosphate method, a lipofection method, an electroporation method and the like can be mentioned.
- the host is a plant, for example, an electroporation method, an Agrobacterium method, a particle gun method, a PEG method and the like can be mentioned.
- polypeptide of the present invention can be produced by culturing the transformant.
- the culture conditions of the transformant may be appropriately set in consideration of the nutritional and physiological properties of the host, but liquid culture is preferable. Further, in the case of industrial production, aeration stirring culture is preferable.
- the transformant of the present invention is cultured, and the culture supernatant or cells are collected by a method such as centrifugation. If the polypeptide of the present invention is accumulated in the cells, the cells are treated with a mechanical method such as ultrasonic waves or French press or a lytic enzyme such as lysozyme, and if necessary, an enzyme such as protease is applied. It can be solubilized by using a surfactant such as sodium dodecyl sulfate (SDS) or a water-soluble fraction containing the polypeptide of the present invention.
- SDS sodium dodecyl sulfate
- the expressed polypeptide of the present invention can be secreted into the culture medium.
- the culture broth or the water-soluble fraction containing the polypeptide of the present invention obtained as described above may be subjected to the purification treatment as it is, but the polypeptide of the present invention in the culture broth or the water-soluble fraction may be used as it is. After concentration, it may be subjected to a purification treatment.
- Concentration can be performed by, for example, vacuum concentration, membrane concentration, salting out treatment, fractional precipitation method using a hydrophilic organic solvent (for example, methanol, ethanol and acetone), or the like.
- a hydrophilic organic solvent for example, methanol, ethanol and acetone
- the purification treatment of the polypeptide of the present invention can be performed, for example, by appropriately combining methods such as gel filtration, hydrophobic chromatography, ion exchange chromatography, and affinity chromatography.
- the polypeptite of the present invention purified in this manner may be powdered by freeze-drying, vacuum-drying, spray-drying or the like, if necessary.
- the polypeptide of the present invention is immobilized on an insoluble carrier and used as an immunoglobulin-binding carrier in order to easily recover and purify the immunoglobulin.
- the insoluble carrier used for immobilization of the polypeptide of the present invention is not particularly limited, but is not particularly limited, and is, for example, naturally derived polymer materials such as chitosan, dextran, cellulose and agarose; synthetic organics such as vinyl alcohol, polyimide and methacrylate. Materials: Examples thereof include inorganic materials such as glass and silica.
- the shape of the insoluble carrier is not particularly limited, and may be any shape such as a hollow fiber membrane shape, a monolith shape, and a bead shape.
- the bead shape is generally suitable because it has a relatively large surface area per volume and is suitable for producing an affinity carrier having a high immunoglobulin binding ability.
- the amino group, carboxyl group, or thiol group in the polypeptide of the present invention may be coupled with the insoluble carrier.
- the insoluble carrier may be activated by reacting with a coupling agent such as cyanogenbromid, epichlorohydrin, N-hydroxysuccinimide, tosilylloride, tresilylloride, carbodiimide, glutaraldehyde, or hydrazine.
- an immobilization method in which a reactive functional group such as a carboxyl group or a thiol group is introduced into the carrier and then a coupling reaction is carried out with the polypeptide of the present invention can be mentioned.
- Such coupling reactions are well known in the art (eg, Janson, J.C., edited [Protein purification], 3rd edition, pp. 221-258, ISBN 978-0-471-74661-. 4) It can be done according to the conventional method.
- a reactive functional group such as toyopearl AF-Tresyl-650, Toyopearl AF-Epoxide-650, Toyopearl AF-carboxy-650, Toyopearl AF-Holmyl-650 (above, Toso Co., Ltd.), NHS activated sepharose, and bromide.
- Cyanogen activated cepharose epoxy activated cepharose (above, GE Healthcare Bioscience Co., Ltd.), Profinity Epoxide (Biorad Co., Ltd.), Glyoxal-Agarose (Agarose Bead Technologies Co., Ltd.), Cellfine Holmill (JNC Co., Ltd.) Etc., and these commercially available products can be used.
- polypeptide of the present invention can be immobilized on the insoluble carrier by adding a condensation or cross-linking reagent such as carbodiimide or glutaraldehyde to the system in which the polypeptide of the present invention and the insoluble carrier coexist.
- a condensation or cross-linking reagent such as carbodiimide or glutaraldehyde
- an insoluble carrier on which the polypeptide of the present invention is immobilized may be used.
- the isolation of immunoglobulin using an insoluble carrier on which the polypeptide of the present invention is immobilized can be performed by an affinity column chromatography method.
- a column packed with an insoluble carrier on which the polypeptide of the invention is immobilized is passed a solution containing the immunoglobulin or the polypeptide containing its Fc region.
- a solution containing the immunoglobulin or the polypeptide containing its Fc region After binding the polypeptide containing munoglobulin or its Fc region to the polypeptide of the present invention, the inside of the column is washed if necessary, and then an eluent adjusted to an appropriate pH is passed through the column. Thereby, the polypeptide containing the immunoglobulin or its Fc region may be eluted.
- the pH of the solution containing the immunoglobulin or the polypeptide containing the Fc region thereof may be 6.5 or more, preferably 6.5 to 8.0.
- the pH of the eluate may be weakly acidic or less, specifically pH 5 or less, but in order to prevent the separated immunoglobulin or a fragment thereof from being exposed to strongly acidic conditions, the eluate may be prepared.
- the pH is preferably 3 to 5, more preferably 3.4 to 4.5, and even more preferably 3.6 to 4.5.
- Test Example 1 Production and evaluation of monodomain-type polypeptide (1) 1.
- Production of monodomain -type polypeptide A monodomain-type polypeptide in which the C domain of protein A was modified was produced.
- the specific manufacturing method is as follows.
- PN-32 The polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 2 was named PN-32.
- the expression plasmid of PN-32 was produced by the following method.
- a double-stranded DNA having a base sequence in which the recognition sequence of the restriction enzyme NdeI, the sequence encoding the amino acid sequence of SEQ ID NO: 2, the translation termination codon, and the recognition sequence of the restriction enzyme BamHI are arranged in this order is synthesized at the site of the translation start codon. It was made using an oligonucleotide. Fragments obtained by cleaving both ends of the synthetic oligonucleotide with the restriction enzymes NdeI and BamHI, respectively, were incorporated into the pET9a plasmid similarly cleaved with these two restriction enzymes by a ligation reaction, and then incorporated into Escherichia coli DH-5 ⁇ competent cells. Transformed. The Escherichia coli was cultured in the presence of kanamycin to purify the PN-32 expression plasmid (pET9a / PN-32).
- the nucleic acid sequence of pET9a / PN-32 thus obtained was analyzed using a CEQ8000 type DNA sequencer (Beckman Coulter Co., Ltd.), and it was confirmed that the sequence was as designed.
- a double-stranded DNA encoding the desired variant was prepared by PCR using pET9a / PN-32 as a template and an oligonucleotide DNA designed and synthesized so as to have one amino acid substitution of interest as a primer.
- pET9a / PN-32 it was cleaved with restriction enzymes NdeI and BamHI and incorporated into the pET9a plasmid by a ligation reaction to obtain an expression plasmid of a PN-32 variant having one amino acid substitution.
- the same operation as described above was carried out to prepare an expression plasmid of the PN-32 variant having two amino acid substitutions.
- the nucleic acid sequence of the expression plasmid of the PN-32 variant thus obtained was analyzed using a CEQ8000 type DNA sequencer (Beckman Coulter Co., Ltd.), and it was confirmed that the sequence was as designed.
- PN-32 and its variants Expression of PN-32 and its variants by transforming Escherichia coli BL21 (DE3) competent cells (Merck Co., Ltd.) with the expression plasmids of PN-32 and its variants obtained above. Got a stock.
- Each expressed Escherichia coli strain of PN-32 and its variants was cultivated for 12 hours in LB medium containing 25 mg / L kanamycin and 2.0% glucose.
- the obtained seed culture solution was inoculated into 2 ⁇ TY medium containing 25 mg / L kanamycin and 0.8% glucose, and cultured at 37 ° C. for 16 hours to express the desired PN-32 and its variants.
- Escherichia coli was recovered by centrifugation.
- the recovered Escherichia coli was suspended in 50 mM sodium phosphate buffer (pH 6.5), ultrasonically treated to crush the Escherichia coli, and further centrifuged to recover PN-32 and its variants in the supernatant.
- PN-32 and its variants were separated by a linear concentration gradient of 0.3 M NaCl. As a result of subjecting each separation solution to SDS-PAGE and confirming the purity, it was confirmed that PN-32 and its variants were purified as a single band at the position of the theoretical molecular weight.
- the absorption of the eluate eluted at pH 4.0 and the eluate eluted at pH 2.8 at 280 nm was measured with a spectrophotometer, and the specific extinction coefficient of 13.8 (1 g -1 cm -1 ) was also obtained.
- the amount of IgG contained in each eluate was determined.
- the amount of human IgG in the eluate eluted at pH 4.0, where the total amount of the human IgG amount of the eluate eluted at pH 4.0 and the human IgG amount of the eluate eluted at pH 2.8 is 100%.
- the ratio was determined as "elution rate (%) in weak acidity".
- Glutamine at position 9 is replaced with an amino acid having a hydrophobic aliphatic side chain (alanine, valine, leucine, or isoleucine), and serine at position 41 is an amino acid having a hydrophobic side chain (alanine, valine, leucine, phenylalanine).
- the variant substituted with, tyrosine, or histidine the residual activity after alkali treatment is higher than that of the monovariant variant at position 41, and the dissolution rate in weak acidity is dramatically improved as compared with PN-32. It was confirmed that.
- the variant in which serine at position 41 is replaced with alanine or leucine has high residual activity after alkali treatment by further substituting glutamine at position 9 with an amino acid or histidine having a hydrophobic aliphatic side chain, and is weakly acidic.
- the dissolution rate was dramatically improved as compared with the monovariant substitution product.
- glutamine at position 9 was replaced with phenylalanine and serine at position 41 was replaced with an amino acid having a hydrophobic side chain, tyrosine, or histidine
- only the residual activity at position 41 was replaced after alkali treatment. It was not higher than the variant.
- Test Example 2 Production and evaluation of monodomain-type polypeptide (2) 1.
- PN-32 SEQ ID NO: 2
- an expression plasmid of the PN-32 variant into which the amino acid substitution shown in Table 2 was introduced was produced by the same method as in Test Example 1.
- the nucleic acid sequence of the expression plasmid of the PN-32 variant thus obtained was analyzed using a CEQ8000 type DNA sequencer (Beckman Coulter Co., Ltd.), and it was confirmed that the sequence was as designed.
- Each expressed E. coli strain of the variant of PN-32 was seed-cultured in LB medium containing 25 mg / L kanamycin and 2.0% glucose for 12 hours.
- the obtained seed culture solution was inoculated into 2 ⁇ TY medium containing 25 mg / L kanamycin and 0.8% glucose, and cultured at 37 ° C. for 16 hours to express the desired PN-32 and its variants.
- Escherichia coli was recovered by centrifugation.
- the recovered Escherichia coli was suspended in 50 mM sodium phosphate buffer (pH 6.5), ultrasonically treated to crush the Escherichia coli, and further centrifuged to recover a variant of PN-32 in the supernatant.
- the cell extract of each expressed Escherichia coli strain of the variant of PN-32 was adjusted to pH 6.0 and then applied to a cation exchanger SP-Sepharose Fast Flow (GE Healthcare Co., Ltd.) column. After washing with 20 mM phosphate buffer (pH 6.0), the protein was eluted from the column with a linear concentration gradient of 0.5 M NaCl. When the eluate was confirmed by SDS-PAGE, the variant of PN-32 was eluted between 0.1 and 0.2 M NaCl. Next, the pH of each eluate containing the variant of PN-32 was adjusted to 9, and then added to the anion exchanger Gigacap Q (Tosoh Corporation) column.
- variants of PN-32 were separated with a 0.3 M NaCl linear concentration gradient. As a result of subjecting each separation solution to SDS-PAGE and confirming the purity, it was confirmed that the variant of PN-32 was purified as a single band at the position of the theoretical molecular weight.
- PN-32 SEQ ID NO: 2
- the 9th position is replaced with an amino acid having a hydrophobic aliphatic side chain
- the 41st position is replaced with an amino acid having a hydrophobic side chain
- the 15th position is replaced with alanine
- 11 In the variant in which the position was replaced with arginine, the alkali stability was improved and the elution rate in weak acidity could be further improved.
- the 15-position is replaced with alanine or histidine
- the 24-position is replaced with glutamine
- the 41-position is replaced with an amino acid having a hydrophobic side chain
- the residue remains after alkali treatment. It was confirmed that the activity was 1.40 times or more that of PN-32, and the dissolution rate in weak acidity was 1.40 times that of PN-32, which was dramatically improved.
- Test Example 3 Production and evaluation of monodomain-type polypeptide (3) 1.
- the specific manufacturing method is as follows.
- PN-128 expression plasmid In the amino acid sequence shown in SEQ ID NO: 2, the polypeptide consisting of the amino acid sequence in which threonine at position 7 is replaced with glutamic acid was named PN-128.
- An expression plasmid of PN-128 was produced in the same manner as in Test Example 1.
- the nucleic acid sequence of the PN-128 expression plasmid thus obtained was analyzed using a CEQ8000 type DNA sequencer (Beckman Coulter Co., Ltd.), and it was confirmed that the sequence was as designed.
- the nucleic acid sequence of the expression plasmid of the PN-128 variant thus obtained was analyzed using a CEQ8000 type DNA sequencer (Beckman Coulter Co., Ltd.), and it was confirmed that the sequence was as designed.
- PN-128 and its variants Expression of PN-32 and its variants by transforming Escherichia coli BL21 (DE3) competent cells (Merck Co., Ltd.) with the expression plasmids of PN-128 and its variants obtained above. Got a stock.
- Each expressed Escherichia coli strain of PN-128 and its variants was cultivated for 12 hours in LB medium containing 25 mg / L kanamycin and 2.0% glucose.
- the obtained seed culture solution was inoculated into 2 ⁇ TY medium containing 25 mg / L kanamycin and 0.8% glucose, and cultured at 37 ° C. for 16 hours to express the desired PN-128 and its variants.
- Escherichia coli was recovered by centrifugation.
- the recovered Escherichia coli was suspended in 50 mM sodium phosphate buffer (pH 6.5), ultrasonically treated to crush the Escherichia coli, and further centrifuged to recover PN-32 and its variants in the supernatant.
- PN-128 and its variants were separated by a linear concentration gradient of 0.3 M NaCl. As a result of subjecting each separation solution to SDS-PAGE and confirming the purity, it was confirmed that PN-128 and its variants were purified as a single band at the position of the theoretical molecular weight.
- Test Example 4 Production and evaluation of a multi-domain polypeptide 1.
- Production of multi-domain polypeptide A multi-domain polypeptide having 6 modified sequences of the C domain of protein A was produced. The specific manufacturing method is as follows.
- PN-621 expression plasmid From the N-terminal side, a polypeptide consisting of an amino acid sequence in which five amino acid sequences (SEQ ID NO: ⁇ ) shown in SEQ ID NO: 3 and one amino acid sequence (sequence ⁇ ) shown in SEQ ID NO: 2 are directly linked in this order is PN-. It was named 621.
- the expression plasmid of PN-621 was produced by the method described in Patent Document 3.
- the nucleic acid sequence of the PN-621 expression plasmid thus obtained was analyzed using a CEQ8000 type DNA sequencer (Beckman Coulter Co., Ltd.), and it was confirmed that the sequence was as designed.
- the nucleic acid sequence of the expression plasmid of the PN-621 variant thus obtained was analyzed using a CEQ8000 type DNA sequencer (Beckman Coulter Co., Ltd.), and it was confirmed that the sequence was as designed.
- PN-621 and its variants Expression of PN-621 and its variants by transforming Escherichia coli BL21 (DE3) competent cells (Merck Co., Ltd.) with the expression plasmids of PN-621 and its variants obtained above. Got a stock.
- Each expressed Escherichia coli strain of PN-621 and its variants was cultivated for 12 hours in LB medium containing 25 mg / L kanamycin and 2.0% glucose.
- the obtained seed culture solution was inoculated into 2 ⁇ TY medium containing 25 mg / L kanamycin and 0.8% glucose, and cultured at 37 ° C. for 16 hours to express the desired PN-621 and its variants.
- Escherichia coli was recovered by centrifugation.
- the recovered Escherichia coli was suspended in 50 mM sodium phosphate buffer (pH 6.5), ultrasonically treated to crush the Escherichia coli, and further centrifuged to recover PN-621 and its variants in the supernatant.
- a multi-domain type polypeptide having a plurality of amino acid sequences substituted with histidine and having an amino acid having a hydrophobic side chain at the 41st position or with histidine It was found that even a multi-domain type polypeptide having a plurality of amino acid sequences in which the 24-position is substituted with glutamine and the 41-position is substituted with histidine also has high residual activity after alkali treatment and IgG elution ability in weak acidity. rice field.
- sequences ⁇ , ⁇ , sequences ⁇ 1 to 12, and sequences ⁇ 1 to 10 shown in Table 4 are as follows.
- Sequence ⁇ Amino acid sequence shown in SEQ ID NO: 3.
- Sequence ⁇ Amino acid sequence shown in SEQ ID NO: 2.
- Sequence ⁇ 1 Amino acid sequence in which the amino acid substitution of A4I / T7R / N11A / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 3.
- Sequence ⁇ 1 Amino acid sequence in which the amino acid substitution of A4I / T7R / N11A / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 2.
- Sequence ⁇ 2 Amino acid sequence in which the amino acid substitution of A4I / T7R / Q9V / N11A / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 3.
- Sequence ⁇ 2 Amino acid sequence in which the amino acid substitution of A4I / T7R / Q9V / N11A / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 2.
- Sequence ⁇ 3 Amino acid sequence in which the amino acid substitution of A4V / T7E / Q9L / E15H / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 3.
- Sequence ⁇ 3 Amino acid sequence in which the amino acid substitution of A4V / T7E / Q9L / E15H / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 2.
- Sequence ⁇ 4 Amino acid sequence in which the amino acid substitution of A4I / T7E / N11H / E15L / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 3.
- Sequence ⁇ 4 Amino acid sequence in which the amino acid substitution of A4I / T7E / N11H / E15L / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 2.
- Sequence ⁇ 5 Amino acid sequence in which the amino acid substitution of A4I / T7E / Q9A / N11A / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 3.
- Sequence ⁇ 5 Amino acid sequence in which the amino acid substitution of A4I / T7E / Q9A / N11A / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 2.
- Sequence ⁇ 6 Amino acid sequence in which the amino acid substitution of A4I / T7E / Q9V / N11A / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 3.
- Sequence ⁇ 6 Amino acid sequence in which the amino acid substitution of A4I / T7E / Q9V / N11A / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 2.
- Sequence ⁇ 7 Amino acid sequence in which the amino acid substitution of A4I / T7E / Q9H / N11A / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 3.
- Sequence ⁇ 7 Amino acid sequence in which the amino acid substitution of A4I / T7E / Q9H / N11A / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 2.
- Sequence ⁇ 8 Amino acid sequence in which the amino acid substitution of A4I / T7R / Q9V / N11A / E15H / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 3.
- Sequence ⁇ 8 Amino acid sequence in which the amino acid substitution of A4I / T7R / Q9V / N11A / E15H / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 2.
- Sequence ⁇ 9 Amino acid sequence in which the amino acid substitution of A4I / T7E / Q9V / N11A / E15A / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 3.
- Sequence ⁇ 9 Amino acid sequence in which the amino acid substitution of A4I / T7E / Q9V / N11A / E15A / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 2.
- Sequence ⁇ 10 Amino acid sequence in which the amino acid substitution of A4I / T7E / Q9L / N11H / E15L / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 3.
- Sequence ⁇ 10 Amino acid sequence in which the amino acid substitution of A4I / T7E / Q9L / N11H / E15L / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 2.
- Sequence ⁇ 11 Amino acid sequence in which the amino acid substitution of N3D / A4A / N6D / T7V / Q9A / N11A / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 3.
- Sequence ⁇ 12 Amino acid sequence in which the amino acid substitution of N3D / A4A / N6D / T7E / Q9V / N11A / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 3.
- Sequence ⁇ 13 Amino acid sequence in which the amino acid substitution of N3V / A4A / N6Q / T7V / Q9I / N11Q / S41V is introduced in the amino acid sequence shown in SEQ ID NO: 3.
- Sequence ⁇ 14 Amino acid sequence in which the amino acid substitution of N3D / A4V / N6Q / T7V / N11Q / E15H / E24Q / S41H is introduced in the amino acid sequence shown in SEQ ID NO: 3.
- Test Example 5 IgG elution profile by pH gradient A human polyclonal is placed in a column packed with a gel carrier on which each multidomain polypeptide of Example 56 (PN-621 variant) and Comparative Example 50 (PN-621) are immobilized. IgG (obtained from Japan Blood Product Organization) was injected and bound. Human IgG was then eluted with a linear pH gradient using 0.1 M citrate buffer at pH 7.2 and 0.1 M citrate buffer at pH 2.3, and the absorbance of the eluate at 280 nm was monitored.
- FIG. 1 shows the result of using Example 56 (PN-621 variant), and (B) shows the result of using Comparative Example 50 (PN-621).
- PN-621 variant shows the result of using Comparative Example 50
- FIG. 1 shows the result of using Example 56 (PN-621 variant)
- FIG. 2 shows the result of using Comparative Example 50 (PN-621).
- human IgG was eluted at pH 4.02.
- the gel carrier on which the multi-domain type polypeptide of Comparative Example 50 (PN-621) was immobilized human IgG was eluted at pH 3.19.
- Test Example 6 Production and evaluation of wild-type monodomain polypeptide and its variants 1.
- An expression plasmid was prepared. Specifically, wild-type domain A (SEQ ID NO: 4), wild-type domain B (SEQ ID NO: 7), wild-type domain C (SEQ ID NO: 1), wild-type domain D (SEQ ID NO: 10), wild-type domain E (SEQ ID NO: 10).
- the nucleic acid sequences of the wild-type single domain polypeptide and the expression plasmids of these variants were analyzed using a CEQ8000 type DNA sequencer (Beckman Coulter Co., Ltd.), and it was confirmed that the sequences were as designed.
- Each expressed Escherichia coli strain obtained above was seed-cultured in LB medium containing 25 mg / L kanamycin and 2.0% glucose for 12 hours.
- the obtained seed culture medium was inoculated into 2 ⁇ TY medium containing 25 mg / L kanamycin and 0.8% glucose, and cultured at 37 ° C. for 16 hours to obtain each wild-type single domain polypeptide of interest and these.
- E. coli was recovered by centrifugation. Next, the recovered E. coli was suspended in 50 mM sodium phosphate buffer (pH 6.5), ultrasonically treated to crush the E. coli, and further centrifuged to remove each wild-type single domain polypeptide and variants thereof. It was recovered in Qing.
- each of the obtained supernatants was subjected to sodium dodecyl sulfate-15% polyacrylamide gel electrophoresis (SDS-PAGE) as a cell extract, each wild-type monodomain polypeptide and variants thereof were produced as intended. It was confirmed that it was done.
- SDS-PAGE sodium dodecyl sulfate-15% polyacrylamide gel electrophoresis
- the cell extract of each expressed Escherichia coli strain obtained above was adjusted to pH 6.0 and then applied to a cation exchanger SP-Sepharose Fast Flow (GE Healthcare Co., Ltd.) column. After washing with 20 mM phosphate buffer (pH 6.0), the protein was eluted from the column with a linear concentration gradient of 0.5 M NaCl. When the eluate was confirmed by SDS-PAGE, each wild-type monodomain polypeptide and variants thereof were eluted between 0.1 and 0.2 MNaCl. Next, the pH of each eluate containing each wild-type monodomain polypeptide and variants thereof was adjusted to 9, and then added to an anion exchanger Gigacap Q (Tosoh Corporation) column.
- an anion exchanger Gigacap Q Tosoh Corporation
- each wild-type monodomain polypeptide and variants thereof were separated by a linear concentration gradient of 0.3 M NaCl.
- SDS-PAGE SDS-PAGE
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
項1. 下記(A)~(C)のいずれかに示すイムノグロブリン結合ドメインを少なくとも1つ含むポリペプチド。
(A)配列番号1~15のいずれかに示すアミノ酸配列において、以下の(i)~(iv)の条件を満たす改変が導入されているアミノ酸配列を含むイムノグロブリン結合ドメイン:
(i)41位のセリンが、疎水性側鎖を有するアミノ酸、チロシン、又はヒスチジンに置換。
(ii)9位のグルタミンが、未置換、或は疎水性脂肪族側鎖を有するアミノ酸又はヒスチジンに置換。
(iii)15位のグルタミン酸又はグルタミンが、未置換、或はアラニン、ヒスチジン、チロシン又はロイシンに置換。
(iv)24位のグルタミン酸又はアラニンが、未置換、配列番号1~12の場合はグルタミン、ヒスチジン又はアラニンに置換、或は配列番号13~15の場合はグルタミン又はヒスチジンに置換。
(B)配列番号1~15のいずれかに示すアミノ酸配列において、前記(i)~(iv)の条件を満たす改変が導入されており、当該改変がなされていない部位のアミノ酸の1個又は数個が置換、付加、挿入及び/又は欠失されてなり、且つ、対応する未改変のアミノ酸配列からなるポリペプチドと比較して、アルカリ安定性が同等以上、且つ弱酸性領域でのIgG溶出能が高いイムノグロブリン結合ドメイン。
(C)配列番号1~15のいずれかに示すアミノ酸配列において、前記(i)~(iv)の条件を満たす改変が導入されており、対応する未改変のアミノ酸配列に対する、当該改変がなされていない部位の配列同一性が80%以上であり、対応する未改変のアミノ酸配列からなるポリペプチドと比較して、アルカリ安定性が同等以上、且つ弱酸性領域でのIgG溶出能が高いイムノグロブリン結合ドメイン。
項2. 前記(A)~(C)に示すイムノグロブリン結合ドメインの中から選択される1個のイムノグロブリン結合ドメインが含まれる単ドメイン型ペプチドである、項1に記載のポリペプチド。
項3. 前記(A)~(C)に示すイムノグロブリン結合ドメインから選択される2個以上のイムノグロブリン結合ドメインが連結されてなる複ドメイン型ペプチドである、項1に記載のポリペプチド。
項4. 前記アミノ酸配列において、9位のグルタミンが疎水性脂肪族側鎖を有するアミノ酸又はヒスチジンに置換されている、項1~3のいずれかに記載のポリペプチド。
項5. 前記アミノ酸配列において、15位のグルタミン酸又はグルタミンが、アラニン又はヒスチジンに置換され、且つ
配列番号1~12の場合は24位のグルタミン酸がグルタミン、又は配列番号13~15の場合は24位のアラニンがグルタミンに置換されている、項1~4のいずれかに記載のポリペプチド。
項6. 前記アミノ酸配列において、41位のセリンが、アラニン、バリン、ロイシン、フェニルアラニン、チロシン、又はヒスチジンに置換されている、項1~5のいずれかに記載のポリペプチド。
項7. 前記アミノ酸配列において、9位のグルタミンが、アラニン、バリン、ロイシン、イソロイシン、又はヒスチジンに置換されている、項1~6のいずれかに記載のポリペプチド。
項8. 項1~7のいずれかに記載のポリペプチドをコードしているDNA。
項9. 項8に記載のDNAを含む組換えベクター。
項10. 項9に記載の組換えベクターを用いて宿主を形質転換して得られる形質転換体。
項11. 項10に記載の形質転換体を培養する工程を含む、項1~7のいずれかに記載のポリペプチドの製造方法。
項12. 項1~7のいずれかに記載のポリペプチドが不溶性担体に固定化されてなる、イムノグロブリン結合用担体。
項13. 項12に記載のイムノグロブリン結合用担体を用いて、イムノグロブリン又はそのFc領域を含有するポリペプチドの分離を行う、イムノグロブリン又はその断片の分離方法。
項14. 前記イムノグロブリン結合用担体にイムノグロブリン又はそのFc領域を含有するポリペプチドを一旦結合させた後に、pH3~5の条件でイムノグロブリン又はそのFc領域を含有するポリペプチドを溶出させる、項13に記載の分離方法。
本発明のポリペプチドの一態様として、下記(A)に示すイムノグロブリン結合ドメインを少なくとも1つ含むポリペプチドが挙げられる。
(A)配列番号1~15のいずれかに示すアミノ酸配列において、以下の(i)~(iv)の条件を満たす改変が導入されているアミノ酸配列を含むイムノグロブリン結合ドメイン:
(i)41位のセリンが、疎水性側鎖を有するアミノ酸、チロシン、又はヒスチジンに置換。
(ii)9位のグルタミンが、未置換、或は疎水性脂肪族側鎖を有するアミノ酸又はヒスチジンに置換。
(iii)15位のグルタミン酸又はグルタミンが、未置換、或はアラニン、ヒスチジン、チロシン又はロイシンに置換。
(iv)24位のグルタミン酸又はアラニンが、未置換、配列番号1~12の場合はグルタミン、ヒスチジン又はアラニンに置換、或は配列番号13~15の場合はグルタミン又はヒスチジンに置換。
(1)配列番号1~15に示す各アミノ酸配列において、9位、15位及び24位が未置換であり、且つ41位がバリン、フェニルアラニン、チロシン、又はヒスチジンに置換されているアミノ酸配列。
(2)配列番号1~15に示す各アミノ酸配列において、15位及び24位が未置換であり、9位がロイシンに置換され、且つ41位がバリン、ロイシン、フェニルアラニン、アラニン、チロシン、又はヒスチジンに置換されているアミノ酸配列。
(3)配列番号1~15に示す各アミノ酸配列において、15位及び24位が未置換であり、9位がバリンに置換され、且つ41位がロイシン、バリン、フェニルアラニン、チロシン、又はヒスチジンに置換されているアミノ酸配列。
(4)配列番号1~15に示す各アミノ酸配列において、15位及び24位が未置換であり、9位がヒスチジンに置換され、且つ41位がバリンに置換されているアミノ酸配列。
(5)配列番号1~15に示す各アミノ酸配列において、15位及び24位が未置換であり、9位がアラニンに置換され、且つ41位がフェニルアラニン、バリン、チロシン、又はヒスチジンに置換されているアミノ酸配列。
(6)配列番号1~15に示す各アミノ酸配列において、15位及び24位が未置換であり、9位がイソロイシンに置換され、且つ41位のセリンがバリン、又はアラニンに置換されているアミノ酸配列。
(7)配列番号1~15に示す各アミノ酸配列において、24位が未置換であり、9位がバリンに置換され、15位がアラニンに置換され、且つ41位がバリンに置換されに置換されているアミノ酸配列。
(8)配列番号1~15に示す各アミノ酸配列において、24位が未置換であり、9位がロイシン又はバリンに置換され、15位がヒスチジンに置換され、且つ41位がバリンに置換されているアミノ酸配列。
(9)配列番号1~15に示す各アミノ酸配列において、24位が未置換であり、9位がバリンに置換され、15位がチロシンに置換され、且つ41位がバリンに置換されているアミノ酸配列。
(10)配列番号1~15に示す各アミノ酸配列において、24位が未置換であり、9位が未置換又はロイシンに置換され、15位がロイシンに置換され、且つ41位がバリンに置換されているアミノ酸配列。
(10)配列番号1~15に示す各アミノ酸配列において、9位が未置換であり、15位がアラニン又はヒスチジンに置換され、24位がグルタミンに置換され、且つ41位がバリン又はヒスチジンに置換されているアミノ酸配列。
(11)配列番号1~15に示す各アミノ酸配列において、9位がロイシンに置換され、15位がスチジンに置換され、24位がグルタミンに置換され、且つ41位がバリンに置換されているアミノ酸配列。
(12)配列番号1~15に示す各アミノ酸配列において、9位がロイシンに置換され、15位がヒスチジン又はロイシンに置換され、24位がグルタミンに置換され、且つ41位がバリンに置換されているアミノ酸配列。
(13)配列番号1~15に示す各アミノ酸配列において、15位が未置換であり、9位がロイシンに置換され、24位がヒスチジンに置換され、且つ41位がバリンに置換されているアミノ酸配列。
(14)配列番号1~15に示す各アミノ酸配列において、9位がロイシンに置換され、15位がヒスチジン又はロイシンに置換され、24位がヒスチジンに置換され、且つ41位がバリンに置換されているアミノ酸配列。
(15)配列番号1~15に示す各アミノ酸配列において、9位がバリンに置換され、15位がヒスチジン又はロイシンに置換され、24位がアラニンに置換され、且つ41位がバリンに置換されているアミノ酸配列。
(B)配列番号1~15のいずれかに示すアミノ酸配列において、前記(i)~(iv)の条件を満たす改変が導入されており、当該改変がなされていない部位のアミノ酸の1個又は数個が置換、付加、挿入及び/又は欠失されてなり、且つ、対応する未改変のアミノ酸配列からなるポリペプチドと比較して、アルカリ安定性が同等以上、且つ弱酸性領域でのIgG溶出能が高いイムノグロブリン結合ドメイン。
(C)配列番号1~15のいずれかに示すアミノ酸配列において、前記(i)~(iv)の条件を満たす改変が導入されており、対応する未改変のアミノ酸配列に対する、当該改変がなされていない部位の配列同一性が80%以上であり、対応する未改変のアミノ酸配列からなるポリペプチドと比較して、アルカリ安定性が同等以上、且つ弱酸性領域でのIgG溶出能が高いイムノグロブリン結合ドメイン。
(i)11位がアラニン、グルタミン、ヒスチジン又はアルギニンに置換。
(ii)配列番号1~12、14及び15の場合は7位がグルタミン酸に置換(配列番号13の場合は7位は未置換)。
(iii)配列番号1~12、14及び15の場合は7位がグルタミン酸に置換(配列番号13の場合は7位は未置換)、且つ11位がアラニン又はバリンに置換。
(iv)4位がイソロイシンに置換、且つ配列番号1~12、14及び15の場合は7位がアルギニン又はグルタミン酸に置換、或は配列番号13の場合は7位が未置換又はアルギニンに置換。
(v)4位がイソロイシンに置換、配列番号1~12、14及び15の場合は7位がアルギニン又はグルタミン酸に置換、或は配列番号13の場合は7位が未置換又はアルギニンに置換、且つ11位がアラニンに置換。
(vi)4位がイソロイシン又はバリンに置換、且つ配列番号1~12、14及び15の場合は7位がグルタミン酸に置換(配列番号13の場合は7位は未置換)。
(vii)3位がアスパラギン酸に置換、配列番号1~12の場合は6位がアスパラギン酸に置換(配列番号13~15の場合は6位は未置換)、配列番号1~12、14及び15の場合は7位がバリン又はグルタミン酸に置換、或は配列番号13の場合は7位が未置換又はバリンに置換、且つ11位がアラニンに置換。
アガロースゲル担体に固定化したポリペプチドに対して、0.1M NaOH水溶液で3回洗浄して同アルカリ溶液に置換した後に25℃にて68時間保温する(アルカリ処理)。次いで、PBSで洗浄した後に、ヒトIgGの結合量(mg/mlゲル)を測定する。アルカリ処理しなかった場合についても、アガロースゲル担体に固定化したポリペプチドのヒトIgGの結合量(mg/mlゲル)を測定する。アルカリ処理しなかった場合のポリペプチドのヒトIgGの結合量を100%として、アルカリ処理後のポリペプチドのヒトIgGの結合量の割合を「アルカリ処理後の残存活性(%)」として算出する。
アガロースゲル担体に固定化したポリペプチドに対して、ヒトIgGを結合させる。次いで、固定化ポリペプチドをPBSで洗浄した後に、0.1Mクエン酸バッファー(pH4.0)を用いて、固定化ポリペプチドに結合しているヒトIgGを溶出させる。続いて、0.1Mグリシン塩酸バッファー(pH2.8)を用いて、固定化ポリペプチドに結合して残存しているヒトIgGを溶出させる。pH4.0で溶出したヒトIgG量とpH2.8溶出したヒトIgG量を測定する。pH4.0で溶出したヒトIgG量とpH2.8で溶出したヒトIgG量との合計量を100%として、pH4.0で溶出したヒトIgG量の割合を弱酸性での溶出率(%)として算出する。
本発明のポリペプチドをコードしているDNA(以下、「本発明のDNA」と表記することもある)は、例えば、スタフィロコッカス・アウレウス(Staphylococcus aureus)由来のプロテインAをコードしているDNAを鋳型として、目的のイムノグロブリン結合ドメインをコードしているDNAをPCR等によって取得し、当該DNAに所望のアミノ酸置換等が導入されるように変異を導入することにより得ることができる。また、本発明のDNAは、遺伝子の合成法によって人工合成することもできる。
本発明のポリペプチドをコードするDNAを含む組換えベクター(以下、「本発明の組換えベクター」と表記することもある)は、発現ベクターに本発明のDNAを挿入することにより得ることができる。
本発明の組換えベクターを用いて宿主を形質転換することによって形質転換体(以下、「本発明の形質転換体」と表記することもある)が得られる。
本発明のポリペプチドは、前記形質転換体を培養することによって製造することができる。
本発明のポリペプチドは、イムノグロブリンの回収や精製を簡便に行うために、不溶性担体に固定化され、イムノグロブリン結合担体として使用される。本発明のポリペプチドの固定化に使用される不溶性担体としては、特に制限されないが、例えば、キトサン、デキストラン、セルロース、アガロースなどの天然由来の高分子材料;ビニルアルコール、ポリイミド、メタクリレートなどの合成有機材料;ガラス、シリカ等の無機材料等が挙げられる。
本発明のポリペプチドは、イムノグロブリンのFc領域に結合するので、IgG、IgM、IgA等のイムノグロブリン、及びこれらのFc領域を含有するポリペプチド(Fc融合タンパク質等)等の分離に使用できる。
1.単ドメイン型ポリペプチドの製造
プロテインAのCドメインを改変した単ドメイン型ポリペプチドを製造した。具体的な製造方法は、以下の通りである。
配列番号2に示すアミノ酸配列からなるポリペプチドをPN-32と命名した。PN-32の発現プラスミドを以下の手法で製造した。
また、配列番号2に示すアミノ酸配列において、表1に示すアミノ酸置換が導入されたPN-32改変体の発現プラスミドを以下の手法で製造した。
前記で得られたPN-32及びその改変体の各発現プラスミドを用いて、大腸菌BL21(DE3)コンピーテントセル(メルク株式会社)を形質転換することにより、PN-32及びその改変体の各発現株を得た。
精製したPN-32及びその改変体をホルミル活性化アガロースゲル担体に10mg/mLゲルの濃度で常法に従って、それぞれ固定化した。固定化後の反応溶液を回収し、固定化率を測定したところ、PN-32及びその改変体の全てにおいて固定化効率が90%以上であった。
PN-32及びその改変体が固定化されている各ゲル担体をPBSで洗浄後、40mg/mLのヒトポリクローナルIgG(日本血液製剤機構より入手)を含むPBS(pH7.5)を加えて1時間振とうした後に、ゲル担体をPBS(pH7.5)で洗浄した。次いで、ゲル担体から0.1M グリシン塩酸バッファー(pH2.8)でゲル担体に結合したヒトIgGを溶出した。その溶出液を分光光度計にて280nmの吸収を測定し、13.8(1g-1cm-1)の比吸光係数をもとに結合したIgG量(IgG結合量)を求めた。
PN-32及びその改変体が固定化されている各ゲル担体をPBSで洗浄後、更に0.1M NaOH水溶液で3回洗浄して同アルカリ溶液に置換した後に25℃にて68時間保存した(アルカリ処理)。次いで、PBSで3回洗浄した後に、前記と同条件でイムノグロブリン結合活性を測定した。アルカリ処理前のそれぞれのIgG結合量を100%としたときのアルカリ処理後の残存IgG結合量の割合を「アルカリ処理後の残存活性(%)」として求めた。
PN-32及びその改変体が固定化されている各ゲル担体をPBSで洗浄後、40mg/mLのヒトポリクローナルIgG(日本血液製剤機構より入手)を含むPBS(pH7.5)を加えて1時間振とうした後に、ゲル担体をPBS(pH7.5)で洗浄した。次いで、0.1Mクエン酸バッファー(pH4.0)を用いて、ゲル担体に結合しているヒトIgGを溶出させた。続いて、0.1Mグリシン塩酸バッファー(pH2.8)を用いて、ゲル担体に結合して残存しているヒトIgGを溶出させた。pH4.0で溶出させた溶出液と、pH2.8で溶出させた溶出液を分光光度計にて280nmの吸収を測定し、13.8(1g-1cm-1)の比吸光係数をもとに各溶出液に含まれるIgG量を求めた。pH4.0で溶出させた溶出液のヒトIgG量とpH2.8で溶出させた溶出液のヒトIgG量との合計量を100%として、pH4.0で溶出させた溶出液のヒトIgG量の割合を「弱酸性での溶出率(%)」として求めた。
結果を表1に示す。この結果、PN-32(配列番号2)において、41位のセリンが疎水性側鎖を有するアミノ酸(バリン、フェニルアラニン)、ヒスチジン又はチロシンに置換されている改変体では、アルカリ処理後の残存活性がPN-32の1.1倍以上であり、弱酸性での溶出率がPN-32の1.2倍以上と向上することが見出された。これらの2つの効果を併せ持つ単変異改変部位は41位だけであった。
1.単ドメイン型ポリペプチドの製造
PN-32(配列番号2)において、表2に示すアミノ酸置換が導入されたPN-32改変体の発現プラスミドを、前記試験例1と同様の手法で製造した。
前記で得られたPN-32の改変体の各発現プラスミドを用いて、大腸菌BL21(DE3)コンピーテントセル(メルク株式会社)を形質転換することにより、PN-32及びその改変体の各発現株を得た。
。次に、PN-32の改変体を含む各溶出液のpHを9に調整した後に陰イオン交換体ギガキャップQ(東ソー株式会社)カラムに添加した。20mMリン酸バッファー(pH7.8)にて洗浄後、0.3M NaCl直線的濃度勾配にてPN-32の改変体を分離した。各分離液をSDS-PAGEに供して純度を確認した結果、PN-32の改変体は理論値の分子量の位置に単一バンドとして精製されていることを確認した。
精製したPN-32の改変体をホルミル活性化アガロースゲル担体に10mg/mLゲルの濃度で常法に従って、それぞれ固定化した。固定化後の反応溶液を回収し、固定化率を測定したところ、PN-32の改変体の全てにおいて固定化効率が90%以上であった。
PN-32及びその改変体が固定化されている各ゲル担体を用いて、前記試験例1と同条件でIgG結合量を求めた。
PN-32の改変体が固定化されている各ゲル担体をPBSで洗浄後、更に0.5M NaOH水溶液で3回洗浄して同アルカリ溶液に置換した後に25℃にて17時間保存した(アルカリ処理)。次いで、PBSで3回洗浄した後に、前記と同条件でイムノグロブリン結合活性を測定した。アルカリ処理前のそれぞれのIgG結合量を100%としたときのアルカリ処理後の残存IgG結合量の割合を「アルカリ処理後の残存活性(%)」として求めた。
PN-32及びその改変体が固定化されている各ゲル担体を用いて、前記試験例1と同条件で弱酸性での溶出率を求めた。
結果を表2に示す。この結果からも、PN-32(配列番号2)において、9位が疎水性脂肪族側鎖を有するアミノ酸に置換、41位が疎水性側鎖を有するアミノ酸に置換、且つ11位がアラニンに置換されている改変体においても、アルカリ処理後の残存活性がPN-32の1.49倍以上であり、弱酸性での溶出率がPN-32よりも1.27倍と飛躍的に向上することが確認された。更に、PN-32(配列番号2)において、9位が疎水性脂肪族側鎖を有するアミノ酸に置換、41位が疎水性側鎖を有するアミノ酸に置換、15位がアラニンに置換され、且つ11位がアルギニンに置換されている改変体では、アルカリ安定性の向上と共に弱酸性での溶出率を更に向上させることができた。また、9位が未置換、15位がアラニン又はヒスチジンに置換、24位がグルタミンに置換、且つ41位が疎水性側鎖を有するアミノ酸に置換されている改変体においても、アルカリ処理後の残存活性がPN-32の1.40倍以上であり、弱酸性での溶出率がPN-32よりも1.40倍と飛躍的に向上することが確認された。
1.単ドメイン型ポリペプチドの製造
プロテインAのCドメインを改変した単ドメイン型ポリペプチドを製造した。具体的な製造方法は、以下の通りである。
配列番号2に示すアミノ酸配列において、7位のスレオニンがグルタミン酸に置換されているアミノ酸配列からなるポリペプチドをPN-128と命名した。PN-128の発現プラスミドを前記試験例1と同様の手法で製造した。
また、配列番号2に示すアミノ酸配列において、表3に示すアミノ酸置換が導入されたPN-128改変体の発現プラスミドを前記試験例1と同様の手法で製造した。
前記で得られたPN-128及びその改変体の各発現プラスミドを用いて、大腸菌BL21(DE3)コンピーテントセル(メルク株式会社)を形質転換することにより、PN-32及びその改変体の各発現株を得た。
精製したPN-128及びその改変体をホルミル活性化アガロースゲル担体に10mg/mLゲルの濃度で常法に従って、それぞれ固定化した。固定化後の反応溶液を回収し、固定化率を測定したところ、N-128及びその改変体の全てにおいて固定化効率が90%以上であった。
PN-128及びその改変体が固定化されている各ゲル担体を用いて、前記試験例1と同条件でIgG結合量を求めた。
PN-128及びその改変体が固定化されている各ゲル担体を用いて、前記試験例2と同条件でアルカリ処理後の残存活性を求めた。
PN-128及びその改変体が固定化されている各ゲル担体を用いて、前記試験例1と同条件で弱酸性での溶出率を求めた。
結果を表3に示す。この結果、PN-128(配列番号2に示すアミノ酸配列において7位がグルタミン酸に置換されたアミノ酸配列)において、9位が疎水性脂肪族側鎖を有するアミノ酸に、41位が疎水性側鎖を有するアミノ酸又はヒスチジンに置換されていることに加え、(i)11位を疎水性側鎖を有するアミノ酸への置換、(ii)15位を疎水性側鎖を有するアミノ酸、チロシン、又はヒスチジンへの置換、(iii)24位をアラニン、グルタミン又はヒスチジンへの置換のいずれか少なくとも1つを有する改変体では、アルカリ処理後の残存活性がPN-128と同等以上であり、弱酸性での溶出率がPN-128よりも飛躍的に向上することが確認された。
1.複ドメイン型ポリペプチドの製造
プロテインAのCドメインの改変配列を6個有する複ドメイン型ポリペプチドを製造した。具体的な製造方法は、以下の通りである。
N末端側から、配列番号3に示すアミノ酸配列(配列α)5個、及び配列番号2に示すアミノ酸配列(配列β)1個がこの順に直接連結されているアミノ酸配列からなるポリペプチドをPN-621と命名した。PN-621の発現プラスミドは特許文献3に記載の方法で製造した。
表4に示すアミノ酸配列を有する置換が導入されたPN-621改変体の発現プラスミドを、前記試験例1及び特許文献3に記載の手法を用いて製造した。
前記で得られたPN-621及びその改変体の各発現プラスミドを用いて、大腸菌BL21(DE3)コンピーテントセル(メルク株式会社)を形質転換することにより、PN-621及びその改変体の各発現株を得た。
精製したPN-621及びその改変体をホルミル活性化アガロースゲル担体に10mg/mLゲルの濃度で常法に従って、それぞれ固定化した。固定化後の反応溶液を回収し、固定化率を測定したところ、N-621及びその改変体の全てにおいて固定化効率が90%以上であった。
PN-621及びその改変体が固定化されている各ゲル担体0.5mL量をTricorn5/20カラム(GEヘルスケア株式会社)にパッキングした。液体クロマトグラフィ装置AKTA pure25(GEヘルスケア株式会社)にセットし、PBSでカラムを平衡化後、3mg/mL濃度のヒトポリクローナルIgG(日本血液製剤機構より入手)溶液を滞留時間5分の流速で流した。カラム通過液の280nmにおける吸光度をモニターし、通過液中のIgG濃度が、使用したIgG溶液の10%濃度に達した時点での添加IgG量を求めた。この値から、下記式に従ってゲル1mL当たりのIgG動的結合量(mg/mL gel)を算出した。
PN-621及びその改変体が固定化されている各ゲル担体を用いて、前記試験例2と同条件でアルカリ処理後の残存活性を求めた。
PN-621及びその改変体が固定化されている各ゲル担体を用いて、前記試験例1と同条件で弱酸性での溶出率を求めた。
結果を表4に示す。この結果、配列番号2又は3において、41位が疎水性側鎖を有するアミノ酸又はヒスチジンに置換されているアミノ酸配列を複数有する複ドメイン型ポリペプチド;9位が疎水性脂肪族側鎖を有するアミノ酸又はヒスチジンに置換され、且つ41位が疎水性側鎖を有するアミノ酸又はヒスチジンに置換されているアミノ酸配列を複数有する複ドメイン型ポリペプチド;並びに、9位が未置換で15位がヒスチジンに置換、24位がグルタミンに置換され、且つ41位がヒスチジンに置換されているアミノ酸配列を複数有する複ドメイン型ポリペプチドでも、アルカリ処理後の残存活性、及び弱酸性でのIgG溶出能が高いことが分かった。
配列α:配列番号3に示すアミノ酸配列
配列β:配列番号2に示すアミノ酸配列
配列α1:配列番号3に示すアミノ酸配列において、A4I/T7R/N11A/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列β1:配列番号2に示すアミノ酸配列において、A4I/T7R/N11A/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列α2:配列番号3に示すアミノ酸配列において、A4I/T7R/Q9V/N11A/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列β2:配列番号2に示すアミノ酸配列において、A4I/T7R/Q9V/N11A/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列α3:配列番号3に示すアミノ酸配列において、A4V/T7E/Q9L/E15H/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列β3:配列番号2に示すアミノ酸配列において、A4V/T7E/Q9L/E15H/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列α4:配列番号3に示すアミノ酸配列において、A4I/T7E/N11H/E15L/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列β4:配列番号2に示すアミノ酸配列において、A4I/T7E/N11H/E15L/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列α5:配列番号3に示すアミノ酸配列において、A4I/T7E/Q9A/N11A/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列β5:配列番号2に示すアミノ酸配列において、A4I/T7E/Q9A/N11A/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列α6:配列番号3に示すアミノ酸配列において、A4I/T7E/Q9V/N11A/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列β6:配列番号2に示すアミノ酸配列において、A4I/T7E/Q9V/N11A/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列α7:配列番号3に示すアミノ酸配列において、A4I/T7E/Q9H/N11A/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列β7:配列番号2に示すアミノ酸配列において、A4I/T7E/Q9H/N11A/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列α8:配列番号3に示すアミノ酸配列において、A4I/T7R/Q9V/N11A/E15H/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列β8:配列番号2に示すアミノ酸配列において、A4I/T7R/Q9V/N11A/E15H/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列α9:配列番号3に示すアミノ酸配列において、A4I/T7E/Q9V/N11A/E15A/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列β9:配列番号2に示すアミノ酸配列において、A4I/T7E/Q9V/N11A/E15A/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列α10:配列番号3に示すアミノ酸配列において、A4I/T7E/Q9L/N11H/E15L/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列β10:配列番号2に示すアミノ酸配列において、A4I/T7E/Q9L/N11H/E15L/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列α11:配列番号3に示すアミノ酸配列において、N3D/A4A/N6D/T7V/Q9A/N11A/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列α12:配列番号3に示すアミノ酸配列において、N3D/A4A/N6D/T7E/Q9V/N11A/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列α13:配列番号3に示すアミノ酸配列において、N3V/A4A/N6Q/T7V/Q9I/N11Q/S41Vのアミノ酸置換が導入されているアミノ酸配列
配列α14:配列番号3に示すアミノ酸配列において、N3D/A4V/N6Q/T7V/N11Q/E15H/E24Q/S41Hのアミノ酸置換が導入されているアミノ酸配列
実施例56(PN-621改変体)及び比較例50(PN-621)の各複ドメイン型ポリペプチドを固定化したゲル担体をパッキングしたカラムに、ヒトポリクローナルIgG(日本血液製剤機構より入手)を注入し結合させた。次いで、pH7.2の0.1M クエン酸バッファーとpH2.3の0.1M クエン酸バッファーを用いて直線的pH勾配をかけてヒトIgGを溶出させ、溶出液の280nmにおける吸光度をモニターした。
1.野生型、単変異型、及び2変異型の単ドメインポリペプチドの製造
プロテインAの5つの各ドメイン(A、B、C、D、E)の野生型単ドメインポリペプチド、及びこれらの改変体の発現プラスミドを作製した。具体的には、野生型ドメインA(配列番号4)、野生型ドメインB(配列番号7)、野生型ドメインC(配列番号1)、野生型ドメインD(配列番号10)、野生型ドメインE(配列番号13)、これらの各野生型ドメインの41位をヒスチジンに置換した単変異改変体、並びにこれらの各野生型ドメインの9位をロイシン及び41位をヒスチジンに置換した2変異改変体の発現プラスミドを前記試験例1と同様の手法で製造した。なお、これらの野生型ドメイン及びその改変体には、ゲル担体に固定化に利用できるように、C末端に5個のリジンを連結した配列とした。
前記で得られた各発現プラスミドを用いて、大腸菌BL21(DE3)コンピーテントセル(メルク株式会社)を形質転換することにより、各野生型単ドメインポリペプチド、及びこれらの改変体の各発現株を得た。
的濃度勾配によりカラムからタンパク質を溶出した。溶出液をSDS-PAGEにて確認したところ、各野生型単ドメインポリペプチド及びこれらの改変体は0.1から0.2MNaCl間に溶出していた。次に、各野生型単ドメインポリペプチド及びこれらの改変体を含む各溶出液のpHを9に調整した後に陰イオン交換体ギガキャップQ(東ソー株式会社)カラムに添加した。20mMリン酸バッファー(pH7.8)にて洗浄後、0.3M NaCl直線的濃度勾配にて各野生型単ドメインポリペプチド及びこれらの改変体を分離した。各分離液をSDS-PAGEに供して純度を確認した結果、各野生型単ドメインポリペプチド及びこれらの改変体は理論値の分子量の位置に単一バンドとして精製されていることを確認した。
精製した各野生型単ドメインポリペプチド及びこれらの改変体をホルミル活性化アガロースゲル担体に10mg/mLゲルの濃度で常法に従って、それぞれ固定化した。固定化後の反応溶液を回収し、固定化率を測定したところ、各野生型単ドメインポリペプチド及びこれらの改変体の全てにおいて固定化効率が90%以上であった。
各野生型単ドメインポリペプチド及びこれらの改変体が固定化されている各ゲル担体を用いて、前記試験例1と同条件でIgG結合量を求めた。
各野生型単ドメインポリペプチド及びこれらの改変体が固定化されている各ゲル担体をPBSで洗浄後、更に0.1M NaOH水溶液で3回洗浄して同アルカリ溶液に置換した後に25℃にて、6時間、17時間、又は68時間保存した(アルカリ処理)。次いで、PBSで3回洗浄した後に、前記と同条件でイムノグロブリン結合活性を測定した。アルカリ処理前のそれぞれのIgG結合量を100%としたときのアルカリ処理後の残存IgG結合量の割合を「アルカリ処理後の残存活性(%)」として求めた。
各野生型単ドメインポリペプチド及びこれらの改変体が固定化されている各ゲル担体を用いて、IgGの溶出に0.1M クエン酸バッファー(pH5.0)を用いたこと以外は前記試験例1と同条件で弱酸性での溶出率を求めた。
結果を表5及び6に示す。この結果から、プロテインAの5つのドメインにおいて、41位をヒスチジンに置換した単変異改変体、並びに9位をロイシン且つ41位をヒスチジンに置換した2変異改変体は、アルカリ処理後の残存活性が野生型よりも同等以上となり、弱酸性での溶出率もそれぞれ向上することが確認された。
Claims (14)
- 下記(A)~(C)のいずれかに示すイムノグロブリン結合ドメインを少なくとも1つ含むポリペプチド。
(A)配列番号1~15のいずれかに示すアミノ酸配列において、以下の(i)~(iv)の条件を満たす改変が導入されているアミノ酸配列を含むイムノグロブリン結合ドメイン:
(i)41位のセリンが、疎水性側鎖を有するアミノ酸、チロシン、又はヒスチジンに置換。
(ii)9位のグルタミンが、未置換、或は疎水性脂肪族側鎖を有するアミノ酸又はヒスチジンに置換。
(iii)15位のグルタミン酸又はグルタミンが、未置換、或はアラニン、ヒスチジン、チロシン又はロイシンに置換。
(iv)24位のグルタミン酸又はアラニンが、未置換、配列番号1~12の場合はグルタミン、ヒスチジン又はアラニンに置換、或は配列番号13~15の場合はグルタミン又はヒスチジンに置換。
(B)配列番号1~15のいずれかに示すアミノ酸配列において、前記(i)~(iv)の条件を満たす改変が導入されており、当該改変がなされていない部位のアミノ酸の1個又は数個が置換、付加、挿入及び/又は欠失されてなり、且つ、対応する未改変のアミノ酸配列からなるポリペプチドと比較して、アルカリ安定性が同等以上、且つ弱酸性領域でのIgG溶出能が高いイムノグロブリン結合ドメイン。
(C)配列番号1~15のいずれかに示すアミノ酸配列において、前記(i)~(iv)の条件を満たす改変が導入されており、対応する未改変のアミノ酸配列に対する、当該改変がなされていない部位の配列同一性が80%以上であり、対応する未改変のアミノ酸配列からなるポリペプチドと比較して、アルカリ安定性が同等以上、且つ弱酸性領域でのIgG溶出能が高いイムノグロブリン結合ドメイン。 - 前記(A)~(C)に示すイムノグロブリン結合ドメインの中から選択される1個のイムノグロブリン結合ドメインが含まれる単ドメイン型ペプチドである、請求項1に記載のポリペプチド。
- 前記(A)~(C)に示すイムノグロブリン結合ドメインから選択される2個以上のイムノグロブリン結合ドメインが連結されてなる複ドメイン型ペプチドである、請求項1に記載のポリペプチド。
- 前記アミノ酸配列において、9位のグルタミンが疎水性脂肪族側鎖を有するアミノ酸又はヒスチジンに置換されている、請求項1~3のいずれかに記載のポリペプチド。
- 前記アミノ酸配列において、15位のグルタミン酸又はグルタミンが、アラニン又はヒスチジンに置換され、且つ
配列番号1~12の場合は24位のグルタミン酸がグルタミン、又は配列番号13~15の場合は24位のアラニンがグルタミンに置換されている、請求項1~4のいずれかに記載のポリペプチド。 - 前記アミノ酸配列において、41位のセリンが、アラニン、バリン、ロイシン、フェニルアラニン、チロシン、又はヒスチジンに置換されている、請求項1~5のいずれかに記載のポリペプチド。
- 前記アミノ酸配列において、9位のグルタミンが、アラニン、バリン、ロイシン、イソロイシン、又はヒスチジンに置換されている、請求項1~6のいずれかに記載のポリペプチド。
- 請求項1~7のいずれかに記載のポリペプチドをコードしているDNA。
- 請求項8に記載のDNAを含む組換えベクター。
- 請求項9に記載の組換えベクターを用いて宿主を形質転換して得られる形質転換体。
- 請求項10に記載の形質転換体を培養する工程を含む、請求項1~7のいずれかに記載のポリペプチドの製造方法。
- 請求項1~7のいずれかに記載のポリペプチドが不溶性担体に固定化されてなる、イムノグロブリン結合用担体。
- 請求項12に記載のイムノグロブリン結合用担体を用いて、イムノグロブリン又はそのFc領域を含有するポリペプチドの分離を行う、イムノグロブリン又はその断片の分離方法。
- 前記イムノグロブリン結合用担体にイムノグロブリン又はそのFc領域を含有するポリペプチドを一旦結合させた後に、pH3~5の条件でイムノグロブリン又はそのFc領域を含有するポリペプチドを溶出させる、請求項13に記載の分離方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022571552A JPWO2022138718A1 (ja) | 2020-12-22 | 2021-12-22 | |
CN202180084489.3A CN116670150A (zh) | 2020-12-22 | 2021-12-22 | 免疫球蛋白结合多肽 |
EP21910858.6A EP4269590A1 (en) | 2020-12-22 | 2021-12-22 | Immunoglobulin-binding polypeptide |
US18/268,941 US20240043478A1 (en) | 2020-12-22 | 2021-12-22 | Immunoglobulin-binding polypeptide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-212695 | 2020-12-22 | ||
JP2020212695 | 2020-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022138718A1 true WO2022138718A1 (ja) | 2022-06-30 |
Family
ID=82157010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/047570 WO2022138718A1 (ja) | 2020-12-22 | 2021-12-22 | イムノグロブリン結合ポリペプチド |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240043478A1 (ja) |
EP (1) | EP4269590A1 (ja) |
JP (1) | JPWO2022138718A1 (ja) |
CN (1) | CN116670150A (ja) |
WO (1) | WO2022138718A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000023580A1 (en) | 1998-10-21 | 2000-04-27 | Affibody Technology Sweden Ab | A method of affinity separation and ligands for use therein |
WO2007097361A1 (ja) | 2006-02-21 | 2007-08-30 | Protenova Co., Ltd. | イムノグロブリン親和性リガンド |
JP2010156687A (ja) * | 2008-12-24 | 2010-07-15 | Millipore Corp | 腐食安定的クロマトグラフィーリガンド |
WO2012165544A1 (ja) * | 2011-06-03 | 2012-12-06 | 独立行政法人産業技術総合研究所 | 酸性域での親和性が低下したプロテインa変異型タンパク質及び抗体捕捉剤 |
JP2013256479A (ja) * | 2012-06-14 | 2013-12-26 | National Institute Of Advanced Industrial Science & Technology | 抗体精製用担体並びにその製造方法及びその用途 |
JP2016523959A (ja) * | 2013-07-10 | 2016-08-12 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | 突然変異免疫グロブリン結合ポリペプチド |
CN112210013A (zh) * | 2019-07-03 | 2021-01-12 | 拜奥普罗塞亚科技有限责任公司 | 碱耐受性亲和色谱配体 |
-
2021
- 2021-12-22 WO PCT/JP2021/047570 patent/WO2022138718A1/ja active Application Filing
- 2021-12-22 EP EP21910858.6A patent/EP4269590A1/en active Pending
- 2021-12-22 CN CN202180084489.3A patent/CN116670150A/zh active Pending
- 2021-12-22 JP JP2022571552A patent/JPWO2022138718A1/ja active Pending
- 2021-12-22 US US18/268,941 patent/US20240043478A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000023580A1 (en) | 1998-10-21 | 2000-04-27 | Affibody Technology Sweden Ab | A method of affinity separation and ligands for use therein |
WO2007097361A1 (ja) | 2006-02-21 | 2007-08-30 | Protenova Co., Ltd. | イムノグロブリン親和性リガンド |
JP2010156687A (ja) * | 2008-12-24 | 2010-07-15 | Millipore Corp | 腐食安定的クロマトグラフィーリガンド |
WO2012165544A1 (ja) * | 2011-06-03 | 2012-12-06 | 独立行政法人産業技術総合研究所 | 酸性域での親和性が低下したプロテインa変異型タンパク質及び抗体捕捉剤 |
JP2013256479A (ja) * | 2012-06-14 | 2013-12-26 | National Institute Of Advanced Industrial Science & Technology | 抗体精製用担体並びにその製造方法及びその用途 |
JP2016523959A (ja) * | 2013-07-10 | 2016-08-12 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | 突然変異免疫グロブリン結合ポリペプチド |
CN112210013A (zh) * | 2019-07-03 | 2021-01-12 | 拜奥普罗塞亚科技有限责任公司 | 碱耐受性亲和色谱配体 |
Non-Patent Citations (3)
Title |
---|
JANSON, J.-C.: "Protein purification", pages: 221 - 258 |
PASTOR JOSE J., GRANADOS GIOVANNA, CARULLA NATÀLIA, RABANAL FRANCESC, GIRALT ERNEST: "Redesign of Protein Domains Using One-Bead-One-Compound Combinatorial Chemistry", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 129, no. 48, 1 December 2007 (2007-12-01), pages 14922 - 14932, XP055945845, ISSN: 0002-7863, DOI: 10.1021/ja073969x * |
TATIANA A. TATSUSOVATHOMAS L. MADDEN, FEMS MICROBIOL. LETT., vol. 174, 1999, pages 247 - 250 |
Also Published As
Publication number | Publication date |
---|---|
EP4269590A1 (en) | 2023-11-01 |
US20240043478A1 (en) | 2024-02-08 |
JPWO2022138718A1 (ja) | 2022-06-30 |
CN116670150A (zh) | 2023-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6950957B2 (ja) | イムノグロブリン結合ポリペプチド | |
AU652124B2 (en) | Stabilized protein or peptide conjugates | |
WO2014046278A1 (ja) | アフィニティー分離マトリックス用タンパク質リガンド | |
WO2012133349A1 (ja) | アフィニティー分離マトリックス用タンパク質 | |
WO2012086660A1 (ja) | アフィニティークロマトグラフィー用担体およびイムノグロブリンを単離する方法 | |
WO2020040307A1 (ja) | イムノグロブリン結合タンパク質、及びそれを用いたアフィニティー担体 | |
EP3483176B1 (en) | Mutated immunoglobulin-binding protein having increased alkaline tolerance | |
KR20170115535A (ko) | 면역 글로불린에 친화성을 갖는 단백질, 및 그것을 사용한 친화성 분리제, 액체 크로마토그래피용 칼럼 | |
CN104593313B (zh) | 用于制备细菌素durancin GL的重组菌、制备方法及应用 | |
CN108059676B (zh) | 一种抗人神经生长因子scFv抗体及制备方法 | |
WO2022138718A1 (ja) | イムノグロブリン結合ポリペプチド | |
Jianhua et al. | Probing the antigenicity of E. coli L-asparaginase by mutational analysis | |
CN109942700A (zh) | 一种重组型荞麦胰蛋白酶抑制剂突变体以及胰蛋白酶亲和材料 | |
WO2003010204A1 (en) | Process for preparation of polypeptides of interest from fusion peolypeptides | |
CN111888797B (zh) | 一种利用亲和免疫介质纯化蛋黄抗体的方法 | |
CN113980880A (zh) | 基因工程菌及其应用和以葡萄糖为原料生产阿洛酮糖的方法 | |
Sviridova et al. | Crystallization and preliminary crystallographic characterization of the iron-regulated outer membrane lipoprotein FrpD from Neisseria meningitidis | |
CN112521480A (zh) | 一种人干扰素-κ突变体及其制备方法 | |
JP7363134B2 (ja) | 免疫グロブリン結合性タンパク質 | |
CN104945488B (zh) | 一种具有免疫球蛋白结合能力的多肽 | |
KR20020014459A (ko) | 양이온성 아미노산이 부가된 융합단백질 및 이를 이용한생물공정의 개선방법 | |
KR102637595B1 (ko) | 알칼리내성이 증가된 면역글로불린-결합 단백질 변이체 및 이의 용도 | |
JP2022034946A (ja) | 免疫グロブリン結合活性を有するポリペプチド | |
KR102014901B1 (ko) | 단백질에 대한 나노운반체로서의 순도 및 안정성이 증진된 바이러스 유사 입자의 제조방법 | |
JP2022045633A (ja) | 抗真菌剤組成物、化合物及び抗真菌剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21910858 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022571552 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180084489.3 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18268941 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021910858 Country of ref document: EP Effective date: 20230724 |